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PHARMACOLOGIC AND GENETIC MANIPULATIONS OF ANGIOTENSIN
SIGNALING IN THORACIC AORTIC DISEASE MODELS

Andrew Milton Peters, B.S.

Advisory Professor: Dianna M. Milewicz, M.D., Ph.D.

Thoracic aortic aneurysms and dissections (TAAD) are a major cause of morbidity
and mortality in patients. Many different risk factors have been associated TAAD, but
hypertension is the largest risk factor. Subsets of TAAD patients have identifiable
syndromic genetic diseases, yet a number of genetic non-syndromic patients have been
identified. Infusion of angiotensin II into mouse models causes aortic disease through
inflammation and fibrosis. An angiotensin type I receptor (AT1R) blocker (ARB) or an
angiotensin converting enzyme (ACE) inhibitor (ACEi) can reverse aortic pathology in some
mouse models. I set out to better understand the relationship between angiotensin and
TAAD in our mouse models, and hypothesized that angiotensin II signaling through the
AT1R contributes to thoracic aortic aneurysm formation in multiple model systems of
disease, and that blocking related receptors in addition to the AT1R, such as the AT2R
and Mas receptor, may have negative consequences. Previously identified genetic variants
in the gene encoding smooth muscle alpha-actin, ACTA2, were modeled with Acta2-/- mice.
vi

I found that the ascending aorta and aortic root in these mice become significantly dilated
over time. Acta2-/- mice are hypotensive, and increasing the blood pressure with a
pharmaceutical and diet based regimen significantly accelerated and worsened the aortic
phenotype. Treatment with losartan, an ARB, attenuated the aortic dilation, but captopril,
an ACEi, did not decrease aortic growth and worsened the disease. Transverse aortic
constriction (TAC) was used to study the ascending aorta and aortic root in response to
increased biomechanical forces. Losartan attenuated the histologic and inflammatory
changes associated with TAC, but captopril was again unable to rescue the phenotype. To
understand why, I investigated other receptors blocked by ACEis: the angiotensin II type 2
receptor (AT2R) and the Mas receptor, a receptor for the Ang1-7 peptide. I found that
cotreatment with captopril and an agonist for the AT2R had similar physiologic effects as
the AT1R blocker despite being unable to prevent the fibrotic and inflammatory
remodeling. In contrast, cotreatment with captopril and an agonist for the Mas receptor
blocked remodeling but did not rescue aneurysm formation. My results, coupled with
clinical data, indicate that fibrosis may be beneficial in the aorta, and show we must
expand our understanding of the angiotensin system in aortic disease.
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Chapter 1 – Introduction

1

1.1 – Structure of the aorta
The aorta is the largest vessel in the body, originating from the heart and serving as
a conduit for blood flow to the rest of the body. Anatomically, it is divided into multiple
sections, starting with the aortic valve (aortic annulus), then the aortic root with the
sinuses of Valsalva, where the left and right coronary arteries branch off to provide blood
to the heart (Figure 1.1). The junction between the root and ascending aorta is the
sinotubular junction, and the tubular ascending aorta extends to the arch. The innominate
artery branches off the aortic arch and divides into the right subclavian artery and right
common carotid artery. The segment through the aortic arch is also known as the
transverse aorta, and the left common carotid artery branches off this segment of the
aorta followed by the left subclavian artery. The descending thoracic aorta runs along the
spine and is where the intercostal arteries originate. Once the aorta passes the diaphragm,
it becomes the suprarenal abdominal aorta and, eventually, the infrarenal abdominal aorta
below the branches of the left and right renal arteries. The aorta ends where it branches
into the left and right iliac artery (1, 2). The sections of the aorta arise from distinct
embryologic origins, experience distinct biomechanical pressures, and as a result may
respond differently to different stimuli (3, 4). In the ascending aorta, all the smooth muscle
cells are of neural crest cell origin. In the aortic root, these cells are derived from the
second heart field (3). In the research presented here, the focus is on the aortic root and
ascending aorta.
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Figure 1.1 – Anatomical figure of the aorta from the heart to the pelvis starting from the
aortic valve annulus where the blood leaves the heart through the aortic valve. The focus
of the research presented here is primarily at the aortic root, which includes the sinuses of
Valsalva, and the ascending aorta. The pathology associated with each segment of the
aorta can be different, in part due to the different developmental origin of the SMCs and
the hemodynamic flow patterns. Reprinted with permission from Journal of the American
College of Cardiology (Weinsaft JW, Devereux RB, Preiss LR, Feher A, Roman MJ, Basson CT,
Geevarghese A, Ravekes W, Dietz HC, Holmes K, Habashi J, Pyeritz RE, Bavaria J, Milewski K,
LeMaire SA, Morris S, Milewicz DM, Prakash S, Maslen C, Song HK, Silberbach GM, Shohet
RV, McDonnell N, Hendershot T, Eagle KA, Asch FM, Investigators GR. Aortic Dissection in
Patients With Genetically Mediated Aneurysms: Incidence and Predictors in the GenTAC
Registry, 2016) (1)

The aortic is an elastic artery and the aortic wall is composed of three layers: the
tunica intima, tunica media, and tunica adventitia. As shown in Figure 1.2, the tunica intima
3

is composed of a single layer of endothelial cells that, under normal physiologic conditions,
rests on the internal elastic lamina and signals changes in sheer stress to the cells
underneath (5-7). Between the internal elastic lamina and the external elastic lamina lies
the tunica media which is the layer containing the smooth muscle cells. In the aorta, the
tunica media is composed of layers of elastin with smooth muscle cells (SMCs) in between,
with all layers laid down during development. In humans, there are approximately 50
layers. The number of layers varies in different species, and this number has been shown to
depend on multiple factors like weight, diameter, and pressure (6). The number of elastin
lamellae/SMCs can also vary in genetically-engineered mouse models (6, 8-11). The layers
of elastin provide the aorta with the elasticity required to store the energy of the heart
beat when the aortic valves close and maintain the blood pressure for continuous blood
flow. This is referred to as the Wendkessel effect. Approximately 50% of the stroke volume
has been reported to be stored in the aorta and proximal blood vessels to perfuse the
peripheral tissues, but some reports indicate that pharmaceuticals can manipulate it (12).
In the aorta, the SMCs are arranged in concentric rings between the elastin layers.
Microfibrils, in which the major protein is fibrillin, are at the tips of elastin extensions
extend from the elastin lamellae and bind to dense plaques or focal adhesions on SMCs
(13) (Figure 1.3). At the cell surface, dense plaques or focal adhesions connect the
microfibrils to the cellular network of contractile filaments, which are made up of the
smooth muscle specific isoforms of α-actin (SM α-actin) and myosin heavy chain (SMMHC). Together, this apparatus of connecting cells and matrix has been termed the
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“elastin-contractile unit,” (9, 14) and as discussed below, perturbations in this unit may be
an important cause of thoracic aortic disease.
The outer layer of the aorta, the tunica adventitia, is composed of fibroblasts and
can contain inflammatory cells with some diseases. In addition, this layer also contains
stem cells capable of differentiating into multiple cell types in the vessel wall but their
significance, function, and origin are still under debate (15-19). From a clinical and
physiological perspective, the extracellular matrix in the adventitia is composed mostly of
collagen, which provides the vessel with the structural integrity to support the wall of the
vessel against high intraluminal pressures. In humans, this layer is also where the vasa
vasorum (blood vessels of the blood vessel) reside, providing oxygen and nourishment to
the vessel wall (13, 20).
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Figure 1.2 – Histology of the aortic wall. A) A hematoxylin and eosin (H&E) stain of a wild
type (WT) mouse aorta. Most of the vessel wall observed is the media with minimal
adventitia and a single layer of endothelial cells. Normally, in mice there is not a sizeable
amount of adventitial layer. B) The adventitial layer is much larger with some forms of
aortic pathology. H&E stain of biomechanically stressed ascending mouse aorta to show
the expansion of the adventitia. C) A Movat stain of the stressed aorta demonstrating the
lumen, media (dark), and adventitial layer, which is composed of cells (red), collagen
(yellow, poorly visualized due to the proteoglycan deposition), and proteoglycans (blue). D)
At higher magnification, the elastin fibers can be seen in black in the medial layer. While
not present in mice, the adventitia would be the location of the small arteries of the vasa
vasorum.
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Figure 1.3 – A drawing of the transverse and longitudinal cross section of the vessel wall
demonstrating the contractile unit. Elastin layers (dense black) are arranged between the
smooth muscle cells, and the contractile fibrils are connected to them in the cell. Reprinted
with permission from Lab Invest (Davis EC. Smooth muscle cell to elastic lamina
connections in developing mouse aorta. Role in aortic medial organization, 1993) (14)

1.2 – Thoracic aortic disease and pathology
Thoracic aortic aneurysms and dissections are a major clinical concern, and
constitute some of the most devastating pathologies plaguing patients. The natural history
of thoracic aortic aneurysms is that they enlarge over time, and with this expansion, are
predisposed to acute aortic dissections. With multiple possible presentations, the
diagnosis of thoracic aortic dissections is often missed by physicians. Acute pain in the
upper thorax radiating to the back or to other parts of the chest can often be mistaken for
a minor ailment, when, in fact, it is an aortic dissection and a clinical emergency.
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Figure 1.4 – Aortic aneurysm formation can lead to aortic rupture or dissection. Far left is
an illustration of a root aneurysm and ascending aortic aneurysm. Stanford Type A
dissections are depicted in the middle. They encompass the ascending aorta and are
considered a clinical emergency. A Stanford Type B dissection is anything distal of the left
subclavian artery (depicted far right). Uncomplicated dissections are medically managed
and electively repaired.

Thoracic aortic aneurysms are closely monitored in patients because they are often
the precursor to an aortic dissection or aortic rupture. A rupture of the vessel wall results
in blood leaving the vascular system causing a patient to bleed out or, depending on the
location, compromise other organs near the structure. A dissection is more complex. The
structure of the vessel (aorta) becomes compromised as the aorta enlarges, and a tear in
the intima allows blood to enter the vessel wall. The blood separates the vessel wall
creating a true and false lumen with the false lumen often being located in the medial layer
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of the wall. Blood pressure builds in the false lumen, and the increase in pressure can cause
the dissection to progress proximally or distally down the vessel wall. The pressure in the
false lumen can often collapse or restrict the blood flow in the true lumen causing distal
malperfusion with clinical symptoms. Furthermore, a dissection can lead to rupture and a
patient exsanguinates out if the vessel ruptured is in a large enough compartment of the
body (21, 22).
Aortic aneurysms and dissections are commonly classified by the Stanford
Classification System, which identifies the need for immediate surgical intervention. Other
classification systems of dissection, such as the DeBakey Classification System are also used
(23). Any dissection between the aortic valve and the left subclavian artery is considered a
Stanford Type A dissection. This is considered a surgical emergency as the dissection can
cause a stroke distally or a hemo-pericardium proximally. Normally, these dissections
require emergent replacement of the vessel or more depending on the patient. Stanford
Type B dissections are distal to the left subclavian artery. Often, these cases are medically
managed but closely monitored. They are only surgically addressed if there are
complications such as mesenteric ischemia, paralysis, or untreatable pain (23).
A vascular aneurysm is defined by a ballooning of a vessel to 1.5 times its normal
size, and indicates a weakening of the vessel wall. Aneurysm formation is accompanied by
pathologic changes that strain the wall, alter its structure, and in theory change the flow
mechanics (24-27). In the aortic root and ascending thoracic aorta, the pathology
associated with aneurysms is usually characterized by a disordering and fragmentation of
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the elastic fibers along with an increase in inflammation. Inflammatory markers produced
by vascular SMCs and fibroblasts, such as IL6 and MCP1, signal inflammatory macrophages
to invade the vessel wall. The macrophages then recruit fibroblasts to begin remodeling
the medial layer and alter the extracellular matrix (28). While the origin of the fibroblast
have been debated (17), they differentiate into myofibroblasts and induce the remodeling
process, including the production of matrix metalloproteases (MMPs), to alter the vessel
wall by cleaving multiple target proteins in the extracellular matrix (29). The remodeling
includes changes in the extracellular matrix with alterations or fragmentation of elastin
fibers, the production of proteoglycans, and the production of adventitial collagen (28, 30).
These changes lead to a loss of the highly structured matrix organization described above.
The resulting disruption of the “elastin-contractile unit” structure can cause aberrant
changes in smooth muscle cells such as apoptosis (31) or hyper-proliferation (5, 9, 11).
By far the most important risk factor for thoracic aortic aneurysms and dissection
(TAAD) is hypertension. Other factors that increase blood pressure and biomechanical
forces on the ascending aorta are body building, weight lifting, and illegal drug use
(cocaine, methamphetamines). Approximately 75% of patients with TAAD have elevated
blood pressure, making it the most significant co-factor in the disease (32). Other factors
that increase the risk for thoracic aortic disease include age and the presence of a bicuspid
aortic valve (8). The disease is significantly more common in males than females. In the
studies reported here, Chapter 4 describes the role of increased biomechanical forces on
the ascending aorta in aortic aneurysm formation.
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There are also multiple genetic changes that predispose to thoracic aortic disease.
Clinical studies have shown that up to 25% of TAAD patients have a first degree relative
with the disease (33-35). These cases with an inherited predisposition can have syndromic
forms of the disease, including Marfan syndrome or Loeys-Dietz syndrome, or can lack
syndromic features. Genetic variants leading to TAAD are typically inherited in an
autosomal dominant pattern with reduced penetrance and variable expression (36).
Mutations contributing to the disease have been found in cell adhesion proteins (FBN1,
COL3A1) (37, 38), transforming growth factor-beta (TGF-β) pathway genes (TGFBR1,
TGFBR2, SMAD3, TGFB2) (5, 39, 40), genes encoding proteins involved in SMC contraction
(ACTA2, MYH11, MYLK) (41-44), and genes associated with survival and metabolism(FOXE3,
MAT2A)(8, 45). Marfan syndrome is caused by mutations in FBN1, which encodes fibrillin-1,
the major component in the microfibrils that link elastin with SMCs in the aorta. Many of
these genes have been extensive studied for their relationship to the canonical TGF-β
pathway. The data presented in this dissertation will focus on mutations in the gene
encoding SM α-actin (ACTA2), which were identified by our lab in 2007 (41).

11

1.3 Angiotensin system

Figure 1.5 –Angiotensinogen is converted to angiotensin I, which is then converted to
angiotensin II via angiotensin converting enzyme (ACE). There are multiple therapeutics
developed that alter this pathway, such as ACE inhibitors and AT1R blockers.

The renin-angiotensin system (RAS) is system that regulates blood pressure. In
response to changes in blood pressure, angiotensinogen, an α2-globulin, is produced by the
liver and converted by renin to angiotensin I (AngI). An angiotensin converting enzyme
(ACE) on the surface of pulmonary and renal endothelium then converts angiotensin I to
angiotensin II (AngII) which binds to AngII receptors to alter multiple cells in the body and
adjust blood pressure. Through the angiotensin II type 1 receptor (AT1R) it leads to the
release of a mineralcorticoid, aldosterone, from the adrenal glands which increase sodium
reabsorbortion kidneys to help control blood pressure (46, 47). There are two
12

pharmaceutical strategies to alter this pathway that are currently used extensively in
patients, one via inhibition of ACE inhibitor (ACEi) the second blocking the AT1R (24).
However, the angiotensin system is much more complex. There is more than one receptor
for angiotensin II (48-51). The AT2R has different effects in cells than the AT1R.
Additionally, there is more than one ACE. The second ACE, ACE2, can convert angiotensin I
and angiotensin II to smaller peptides Ang1-9 and Ang1-7, respectively, which lead down a
different pathway triggering the Mas receptor. Additionally, Ang1-9 is converted by ACE to
Ang1-7, which is the ligand for the Mas receptor. These pathways are further discussed
below and shown in Figure 1.6.
The AT2R has been known to counter the effects of the AT1R downstream in
multiple systems. In the vascular SMCs, the AT1R increases proliferation, fibrosis, MMP2,
and MMP9 expression (52), while the AT2R decreases proliferation, fibrosis, and MMP9
expression (48). However, in some models the AT2R has been thought to affect smooth
muscle cell apoptosis (53, 54). Evidence indicates that Ang1-9 is converted by ACE to Ang17. With Ang1-7 binding to the Mas receptor on cardiomyocytes, it increases heart function
improving cardiac output, cardiac index, and fractional shortening. It also reduces
cardiomyocyte hypertrophy, fibrosis, and inflammation, but the Ang1-7 peptide and AngII
have been viewed as having different effects on different physiologic systems, commonly
focused on inflammation and fibrosis (55, 56).
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Figure 1.6 – The revised view of the renin-angiotensin system. AngII can activate both the
AT1R and AT2R receptors. AngI and AngII can both be metabolized by a second ACE
enzyme into angiotensin peptides Ang1-9 and Ang 1-7, respectively.

1.4 Angiotensin in animal models
The role of the angiotensin system in aortic disease has been studied extensively in
mouse models. The infusion of AngII into a mouse at a high enough dose can cause aortic
disease. Most of the studies on angiotensin infusions focus on abdominal aortic aneurysms,
since this and increased blood pressure are the most common presentations with this
model, but expansion and dilation of the ascending aorta coupled with structural changes
are also seen (57). AngII infusion causes medial expansion via hypertrophy or hyperplasia in
both the abdominal and the thoracic aorta. Additionally, it has been shown to increase
inflammation with the secretion of inflammatory cytokines by fibroblast and cells in the
adventitia to recruit monocytes which further stimulate fibroblasts to remodel and
increase cytokine production. Of note, however, blood pressure does not play the only role
14

as an increase in blood pressure with norepinephrine does not have the same effects (28,
30, 58).
There have been multiple studies using manipulation of the angiotensin system in
genetic models of aneurysm formation to study the role of this pathway in driving the
disease. There are a few different mouse models of Marfan syndrome which have variable
effects on pathology and survival. These models include models that are deficient in
fibrullin-1 (Fbn1-/-) (59) or express only a small percentage of normal fibrillin Fbn1mgR/mgR(8,
60). One of the most established models is the Fbn1C1039G/+ mouse model (61, 62), which is
viable and exhibits slow aortic growth. This mouse is heterozygous for a missense mutation
that results in production of mutant fibrillin-1. In these mice, it was shown that the
traditional beta-blocker (propranolol) and TGFβ neutralizing antibodies were able to
reverse some of the aortic pathology. The idea was that propranolol would decrease blood
pressure and stress on the aortic wall and the TGFβ neutralizing antibodies would block
pathologic TGFβ signaling. However, an Angiotensin II type I receptor blocker (ARB),
losartan, had a more drastic effect altering the structure of the aortic wall with decreased
elastin fiber disruption, decreased wall thickening, and decreased distance between the
elastic fibers (61). This echoes multiple studies showing the beneficial effects of blocking
the AT1R or knocking it out in mice not just in the aorta, but also the heart (63, 64).
One study also focused on the effects of the AT2R. Agtr2-/- mice were crossed with
Fbn1C1039G/+ mice, which lead to an increase in pERK signaling, a downstream indicator of
AT1R signaling (48). These results indicated that the AT2R may counter many of the
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intracellular effects of the AT1R. Another mouse model of TAAD with a deletion in fibulin-4
(Fbln4-/- mice) causes aneurysm formation with severe medial degeneration along with a
loss of SMC differentiation and hyper proliferation. In these Fbln4-/- mice, the angiotensin
converting enzyme inhibitor captopril was shown to be just as effective as losartan:
initiating treatment with either drug in the first month of life attenuated the growth of the
aorta and reduced pathologic changes in this model (65).
Our lab developed a more acute biomechanical model, in which I focused on hyperacute aortic remodeling model using transverse aortic constriction (TAC) (52). The model
was originally designed to mimic congestive heart failure and has been studied extensively
in congestive heart failure and left ventricular hypertrophy (66). Over two weeks I saw an
increase in proximal aortic size of 23%. There was an increase in the thickness of the media
and adventitia. Medial cell density did not change, but cell density did increase in the
adventitia. Inflammatory markers rose significantly as indicated by expression of IL6 and
MCP-1. Additionally, I observed an increase in matrix remodeling genes MMP2 and MMP9.
I also observed evidence of increased TGFβ signaling. As in other studies, losartan
attenuated many of the pathophysiologic changes associated with this model. Specifically,
losartan attenuated aortic growth, reduced medial thickening, and blocked the
inflammatory response including the infiltration of macrophages. However, losartan was
not able to completely reverse the changes in the adventitial layer, including thickening,
collagen production, and signaling changes (52). Our data, combined with the prior studies
by other labs (61, 65), indicate that AT1R may be a therapeutic target in ascending aortic
disease.
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1.5 Hypothesis tested
I hypothesize that angiotensin II signaling through the AT1R contributes to
thoracic aortic aneurysm formation in multiple model systems of disease, but that
blocking related receptors in addition to the AT1R, such as the AT2R and Mas receptor,
may have no effects or negative consequences.
Herein, I demonstrate that losartan prevents aortic aneurysms in a mouse model of
ACTA2 mutations, Acta2-/- mice, but captopril increases the growth of the aorta. Instead of
increased production of AngII in the aorta, I determined that the loss of α-actin filaments in
aortic SMCs increases NF-κB signaling, thus driving increased expression of AT1R receptor,
sensitizing the cells to exogenous AngII. Furthermore, I show that in an acute
biomechanical stress model, blocking AngII production using an ACE inhibitor (captopril) is
not sufficient to reverse the aortic enlargement associated with the increased pressure.
The addition of an AT2R agonist coupled with captopril prevented aortic growth in a
manner similar to losartan. Lastly, unrecognized congenital abnormalities in the aorta of
the Agtr1-/- mice prevented the use of this model to confirm that losartan prevention of
aortic enlargement with increased biomechanical forces was specifically due to blocking
the AT1R receptor. This is an unexpected, totally novel observation.
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Chapter 2 – Methods
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2.1 Introduction
Similar methods are used in all projects and will be described in this section. When I
chose to make small adjustments from these approaches in different projects, I will
mention those accordingly.

2.2 Mouse models
Mice were housed either at the animal care facility (CLAMC) at The University of
Texas Health Science Center McGovern Medical School Building or in the Mouse
Cardiovascular Phenotyping Core at Baylor College of Medicine. Wild type (WT) mice for
transverse aortic constriction (TAC) were all acquired from Jackson Labs (Bar Harbor, ME,
C57BL/6J Stock No:000664) at 10-12 weeks of age. Upon arriving, mice were quarantined,
and the TAC surgery was performed at 12-14 weeks of age. Mice were sacrificed two weeks
post-operatively as described below. Our lab had previously obtained frozen embryos of
the Acta2-/- mouse from Dr. Warren Zimmer at Texas A&M, originally designed by
Schildmeyer et al and bred into a C57BL6 background (67). Acta2-/- mice were then bred in
house for our studies. In our Agtr1a-/- studies, mice were acquired from Jackson Labs (B6.
129P2-Agtr1aTm1Unc/J, Stock No: 002682). Studies with TAC and Acta2-/- treated with
captopril were all male while the other studies consisted of both male and female mice.
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2.3 Transverse aortic constriction (TAC)
All mouse experimental procedures were approved by the Animal Welfare
Committee at The University of Texas Health Science Center McGovern Medical School and
the Animal Welfare Committee at Baylor College of Medicine Mouse Phenotyping Core.
C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME) at 10-11 weeks
of age. As previously described in Kuang et al (52), mice were administered buprenorphine
preoperatively (0.1 - 2.5 mg/kg subcutaneous injection). Mice were then given 2 – 2.5%
isoflurane with 0.5 to 1.0 L/min of 100 % oxygen via a nose cone. Neck and chest hair was
removed and the surgical site was prepared with chlorohexidine and 70% ethanol. Surgical
instruments were sterilized chemically or by steam autoclave and the surgical area
prepared accordingly. Sterile technique was used throughout. For surgery, the mouse was
placed in a supine position. After administering bupivacaine, a midline incision was made
and superficial tissues were divided to expose the trachea to intubate the trachea using an
18 – 21 gauge catheter. The catheter was then connected to a rodent ventilator (MiniVent,
Type 845) administering 100% oxygen and 2 – 2.5% isoflurane. Mice were kept at a
respiratory rate of 100-125 breaths per minute with a tidal volume of approximately 0.150.25 mL. A partial sternotomy was performed to the second rib and the thymus divided to
expose the transverse aorta. A blunt 27 gauge needle was placed on the transverse aorta
between the right innominate and left carotid artery. Constriction was then made by tying
a 6-0 non-absorbable braided black silk suture around the transverse aortic arch and
needle. The needle was removed yielding the constriction. The chest was closed with two
interrupted vicryl 5-0 sutures after the lungs were re-inflated by closing of the outflow on
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the rodent respirator. The skin was closed using 5-0 non-absorbable suture which was
removed 10 days post-operatively. Anesthesia was discontinued and the animal extubated
once it resumed spontaneous breathing. Mice were monitored closely post-operatively for
signs of distress and discomfort. The sham group underwent an identical procedure but no
suture was tied to the aorta. Adequacy of the constriction was confirmed by Doppler flow
studies, echocardiography, and catheter measurements described below.

Figure 2.1 –The mice are constricted at the site of the transverse aorta leading to an
increase in ascending aorta and aortic root size at two weeks. With the proximal increase in
pressure, flow in the right carotid would increase significantly compared to the left carotid
and there would be a significant pressure drop across the site of the constriction.

2.4 Echo & Doppler studies
Echocardiographic, Doppler, and blood pressure studies were all done in
accordance with protocols previously described (11, 52). Under anesthesia, measurements
were performed with a Vevo700, Vevo2100, Vevo3100, or an Indus Instruments Doppler
system. Briefly, for all echo studies the mice were weighed and placed under anesthesia
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with isoflurane administered and maintained via nose cone with a dose of 1 – 2%
isoflurane at a rate of 0.5 to 1.0 L/min of 100 % oxygen. Mice were maintained under
anesthesia for the duration of the experiment with a goal heart rate of 300 to 400 bpm.
Heart rate and temperature were continuously monitored, and the temperature
maintained within normal limits using the Indus Instruments pad and system. I observed
some variability in response to anesthesia even within groups, with some mice appearing
more sensitive to the anesthesia. Therefore, anesthesia was adjusted accordingly. All
images were obtained in a parasternal long-axis view with 40 MHz ultrasonic probes.
With all experiments performed with the Vevo700 and Vevo2100 systems
(VisualSonics, Toronto, Ontario, Canada), the mice were placed in a supine position on the
monitoring pad angled slightly to the mouse’s left side. Images of the ascending aorta and
aortic root were then obtained and multiple videos recorded for each mouse. Under similar
monitoring and anesthesia, Doppler measurements were made with the Indus Instruments
Doppler probe one week post-operatively and recorded with their Doppler Signaling
Processing Workstation with the mouse supine.
The same procedures were performed using the Vevo3100 (VisualSonics, Toronto,
Ontario, Canada) for ascending and aortic root measurements. However, with the 3100
system, with the mice still sedated, I also assessed cardiac function and flow across the
constriction at the transverse aorta, left common carotid artery, and right common carotid
artery. Flow across the transverse aorta was obtained with the mouse still in the supine
position. Cardiac function was assessed by obtaining both longitudinal and transverse
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views across the left ventricle with the animal tilted slightly to its right in the supine
position. Images over the left common carotid artery and right common carotid were
obtained with the mouse in the Trendelenburg position.
All mice were removed from isoflurane and allowed to recover. Flow studies of the
common carotid arteries using the Vevo3100 correlated with the Indus Instruments
Doppler studies. These studies were done using similar techniques, but the mice were not
required to have their hair removed.
Images of the ascending aorta and aortic root were then obtained, recorded, and
later analyzed using VevoLAB 1.7.1 (VisualSonics, Toronto, Ontario, Canada) or Sante
DICOM Editor 3.1 (Santesoft) (Figure 2.2). Carotid Doppler measurements were also
analyzed with the VevoLAB 1.7.1 when obtained with either the Vevo 3100 or the Doppler
Signal Processing Workstation, Ver 1.624 (Indus Instruments, Houston, Texas).

Figure 2.2 – Echo image of the aorta in the longitudinal view. Measurements were taken at
the ascending aorta and the aortic root. Images taken using the Vevo 700 and analyzed in
the SanteDICOM Software. The red lines designate the measurements for the ascending
aorta (left) and aortic root (right). The heart would be to the right of the image.
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2.5 Non-invasive blood pressure monitoring and blood pressure measurements
Non-invasive blood pressure monitoring was performed via a tail cuff system and
were not utilized in TAC experiments. Briefly, awake mice were immobilized, and a blood
pressure cuff placed over the tail. Mice were then placed on a heating pad and the blood
pressure was recorded for five minutes with a CODA Noninvasive Blood Pressure system
(Kent Scientific Corporation, Torrington, CT). This procedure was repeated multiple days in
a row in order to acclimate the mouse to the testing environment and technique. Only the
measurements on day five were utilized for analysis.
For TAC studies I utilized an invasive, non-survival catheterization technique with a
SPR-1000 1F Catheter (AD Instruments, Sydney, Australia), a Pressure Control Unit PCU2000 (Millar, Houston, TX), a PowerLab 4/35 DAQ device (AD Instruments), and LabChart
software (AD Instruments). Prior to the procedure, all surgical instruments and supplies
were sterilized by steam autoclave, and the surgical field prepared in a sterile fashion. The
1F pressure catheter probes were presoaked in saline or distilled water for 30 second
before catheterization. Mice were anesthetized with isoflurane via nose cone using the
same method previously described for echocardiography (Section 2.4). Ketoprofen was
given subcutaneously at a dose of 2.5 mg/kg. Hair on the chest and throat was removed,
and the skin was prepared with povidone iodine and alcohol. A longitudinal incision was
made approximately 2 mm to the right of the midline of the throat, from the lower jaw to
the sternum. The skin and overlying tissue was gently divided and the right carotid artery
24

exposed. Ligatures were then placed on the right common carotid artery at the proximal
and distal sites. The knot on the distal site was made tight, while that on the proximal
location site was made loose around the artery. Using a hemostat, the artery was clamped
proximal to the more proximal ligation site. A 27 G needle was then used to create a small
hole near the distal ligation site. The catheter probe was then inserted and advanced past
the proximal knot, and the knot tightened down around the probe. For reference, the
depth to insert the probe into a carotid for an 11-week-old mouse would be about 12 mm.
Next, the hemostat was removed and the blood pressure recorded for a 5-10 minutes.
Afterwards, the mouse was euthanized, while still sedated, for studies described below.
2.6 Drug administration
Captopril and Losartan are orally administered drugs used in both our TAC and
Acta2-/- trials. Captopril (Cat# sc-200566A, Santa Cruz Biotechnology) was administered at
75 mg/L and Losartan Potassium (Cat# sc-204796A, Santa Cruz Biotechnology) was
administered at 600 mg/L in the drinking water, as previously (52). For the studies using
AVE0991 (Sanofi, Paris, France), captopril was given in the drinking water and AVE0991
given by intraperitoneal (IP) injection at a dose of 576 ug/kg/d. Similarly, Compound 21
(C21, Vicore, Moelndal, Sweden) was administered by IP injection at a dose of 300 ug/kg/d
with or without captopril in the drinking water.
For the Acta2-/- studies, mice were treated long term with captopril via drinking
water at a dose of 75 mg/L starting at four weeks of age. The mice remained on this dose
until they were sacrificed at 13 months of age, for a total of 12 months of treatment.
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Similarly, mice treated with losartan, were given 600 mg/L in the drinking water starting at
4 weeks of age (11). Losartan treatment was continued for 10 months until sacrifice at 11
months of age. Some mice were also treated long term with doxycycline for approximately
12 months starting at 4 weeks of age. Doxycycline was administered in their drinking water
with 1% sucrose. Controls for all of these experiments were untreated mutant and WT
littermates given drinking water, except in the doxycycline trial in which the control mice
were given 1% sucrose water. The doxycycline doses were based on previous studies (63,
68).
Additional cohorts of Acta2-/- mice were treated short-term with L-NG-nitroarginine
methyl ester (L-NAME) in their drinking water (3 g/L) in conjunction with a high salt diet
(8% NaCl diet, Harlan), to make the mutant mice normotensive. Mice were started on LNAME and high salt diet at 4 weeks for age and treated for 3 months prior to sacrifice at 4
months of age.
2.7 Histomorphometric study
Following completion of the echo, Doppler, and catheterization studies, animals
were sacrificed. After anesthetization with 2.5% avertin, transcardiac perfusion was
performed with 10 mL of PBS for 5 minutes followed by fixation with 10 mL of formalin for
5 minutes. The heart, aortic root, ascending aorta, descending thoracic, and left and right
carotid arteries were then carefully removed and placed in 10% formalin overnight. On the
next day, the tissue was cleaned, processed and embedded in paraffin wax in a transverse
orientation. Tissues were cut into 4 µm sections using a microtome and mounted on slides
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for staining. Hematoxylin and eosin (H&E) staining was performed via standard protocols.
Pictures of the vessel cross-sections were taken at 40x, 50x, 200x, and 400x magnification.
The luminal, medial, and adventitial areas were measured for each vessel in ImageJ. In
addition, cell density was also assessed utilizing ImageJ. Movat staining was used to assess
the structure, elastin breaks, and the amount of elastin and proteoglycan in the vessel wall.
Additional staining of Mac-2 cells (anti-Mac-2 monoclonal antibody for macrophages),
Sirius Red, and α-actin (anti-SMC α-actin specific antibody) were also obtained to look at
inflammation, collagen production, and smooth muscle cells/fibroblast. TUNEL and PH3
staining was also performed to analyze apoptosis and proliferation, respectively. Five or
more mice were analyzed for each group and averaged, but the number of mice depended
on the specific study. Some of the preliminary studies have smaller “n” sizes. Table 2.1
shows the stains and antibodies utilized for these studies.

Table 2.1 – Antibodies and stains utilized for IHC studies including their company and
catalog number.
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2.8 ImageJ analysis
Images were recorded with a DP71 light microscope (Olympus, courtesy of
Blackburn Lab) at 40x and 400x magnification, and all analysis was performed using ImageJ
1.47v (NIH). I utilized 40x magnification as a baseline and method of orientation for
analysis. Cross-sectioned H&E’s at 40x were used to measure luminal area, vascular wall
area, medial area, and adventitial area. Luminal area was defined as the area contained
within the endothelium. However, in reality it is best measured to the internal elastic
lamina, and echo measurements are considered a more physiologic standard. Vascular area
was defined as everything from the internal elastic lamina to the tunica externa, the outer
most defined layer of the vessel wall. Medial area was defined as the area between the
internal elastic lamina and external elastic lamina. The adventitial area was defined as the
area between the external elastic lamina and the tunica externa. Note this area was often
omitted in the sham treated mice because it is very small and more difficult to quantify. In
all mice, the endothelium is omitted since it is a single layer of cells and also difficulty to
quantify.
The 40x images were used to select sections at equivalent locations that were
appropriately distributed throughout the aortic wall for analysis. The majority of the
analysis was done at 400x. On H&E stained sections, cell nuclei were counted using a cell
counter and individually the cellular density of the media and adventitia was determined in
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each image. Over 6 images were analyzed for each section and averaged to calculate,
which I once normalized to the area of each image. Measurements were verified by looking
at multiple cuts of the same aorta.
Images for Movat analysis were taken in a similar fashion at 400x magnification and
analyzed in ImageJ. All components stained by Movat (elastin, collagen, proteoglycan,
fibrin and smooth muscle cells) were assessed and presented as percentages registered
pixels of the segment of interest for quantification. I focused primarily on elastin (black),
proteoglycans (blue), and the cells which stained (red). A band pass filter was used for
analysis, which allowed us to identify color thresholds for hue, saturation, and brightness
for each measured component (i.e. elastin, proteoglycan, and smooth muscle cells). The
resulting images were then used for quantification by the number of pixels.
Mac-2 staining was quantified by manually counting the total number of Mac-2
positive cells in each section. The sirius red, TUNEL, and PH3 stains and images were not
quantified for the purpose of these studies.

2.9 Measurement of ROS in aortas by dihydroethidium (DHE)
Descending aortas were harvested, rinsed immediately in cold PBS, placed in TissueTek OCT compound (Miles Laboratories), and snap frozen in liquid nitrogen. Blocks were
cut to 30 μm-thick cryosections on a cryostat. Frozen sections were fixed in 4% PFA at
room temperature for 15 minutes and rinsed 3x with PBS. DHE (Invitrogen, Cat#C10422)
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stock at 2.5 mM was diluted for a final concentration of 10 μM in PBS and applied to each
tissue section. Slides were incubated in a light-protected humidified incubator at 37°C for
30 minutes. DHE was counterstained with DAPI. Sections were imaged within 8 hours of
staining with a fluorescent ZEISS AXIOSKOP 40 microscope. Identical acquisition settings
were used for tissue from wild-type or mutant animals. Fluorescence images were
quantified with ImageJ. Integrated fluorescence intensity (IFI) was calculated by integrating
the area and strength of red staining within the aortic wall in each image. Error bars
represent standard error.

2.10 RNA extraction and qPCR
Following the echo, Doppler, and catheterization studies, RNA was extracted from
the ascending and descending aorta of a subset of the mice. For RNA extraction, the mice
were perfused with saline and the tissue harvested, cleaned, and then flash frozen. Trizol
(Invitrogen) was used for the extraction of RNA. RNA was then reverse transcribed using
the cDNA Archive Kits (Life Technologies) or iScript cDNA synthesis kit (Bio-Rad) following
the manufacturer protocols. For real-time PCR analysis of mRNA expression, I utilized both
TaqMan (Applied Biosystems, Foster City CA) and SyberGreen primers. SybrGreen probes
were designed as described in the Table 2.2 with references. When mentioned, I
acknowledge the catalog number for the Taqman probes that were used. Experiments
were performed in triplicate, and Gapdh was used as an endogenous control for each run.
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Table 2.2 – Primers designed from SybrGreen utilized in our studies.
“2.11 2D-gel electrophoresis
Cultured SMCs or freshly isolated ascending aortic tissue were
homogenized in urea sample buffer, containing 8M urea, 20mM Tris,
23mM glycine, 0.2mM EDTA, 5% saturated sucrose, and 10mM DTT.
Three micrograms of cell lysates mixed with or without 200ng of purified
SM α-actin or SM γ-actin (provided by Dr. Kathleen Trybus from the
University of Vermont) were added into 450µL of Rehydration/Sample
buffer (Bio-Rad). Samples were loaded onto 24 cm, pH 4–7, immobilized
pH gradient strips (Bio-Rad) overnight and focused in a PROTEAN® i12™
IEF System (Bio-Rad) for 60kVh. Then, the strips were equilibrated in
Equilibration Buffer I and II (Bio-Rad), the center third parts were cut out
and saved, and the strips were gently inserted into a 8-12% SDS-PAGE
mini-gel (Bio-Rad). Then, the gel was run, transferred to nitrocellulose
membrane, blotted with anti-pan actin antibody (MA5-11869, Sigma),
and visualized as described in routine immunoblotting. The calculated
isoelectric points for α-, β-, and γ-actin are 5.24, 5.29, and 5.31,
respectively.
2.12 NADPH oxidase activity assay.
Aortic tissues harvested from 2 months old mice (n=4 per group)
were ground in chilled grinding vials and were homogenized in lysis
buffer (20 mmol/l KH2PO4, 1 mmol/l EGTA, and protease inhibitors
cocktail; pH 7.4) and sonicated for 5s (3x with 10s interval). The
homogenates were then centrifuged at 750 g for 5 min. The pellet was
discarded and the supernatant was collected and subjected to a
lucigenin-enhanced luminescence assay as described before to determine
NADPH oxidase activity in the aortic tissue homogenate (69). Protein
content was measured in an aliquot of homogenate by Bradford assay.
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NADPH oxidase activity was measured by chemiluminescence in a well
containing assay phosphate buffer (50 mM KH2PO4, 1 mM EGTA, and 150
mM sucrose; pH 7.4), 5 μM lucigenin (Sigma), and the sample (50 μl).
Reactions (final volume, 250 μl) were initiated by addition of 100 μM
NADPH (Sigma). Luminescence was measured every second for 5 min in a
luminometer (BioTek Synergy™ HT; BioTek Instruments, Inc., Winooski,
VT). A background value was subtracted from each reading. Activity was
calculated from the ratio of mean light units to total protein level and
expressed as arbitrary units (relative light unit).
2.13 Calcium imaging
Cells were seeded on 25mm coverslips and pretreated with the
indicated drugs for the indicated times. Cells were loaded with Fura-2AM
for 10-15 minutes and then placed in the imaging chamber with 0.5mL of
culture medium. Coverslips were mounted for viewing on a Nikon TE200
microscope, and imaging was performed with Incytim2 software
(Intracellular Imaging, Inc.). Measurements were taken using excitation
wavelengths of 343/380 nm and emission wavelength of 520 nm. Basal
Ca++ was assessed for 20 seconds, then 0.5mL of medium containing the
indicated amounts of AngII was added to the chamber. Imaging
continued until Ca++ levels returned to baseline. Data is represented as
Fmax/F0 where Fmax represents the highest 340/380 ratio and F0
represents the baseline 340/380 ratio for each cell.”
Quoted text reprinted from Supplemental Information with minimal
modification with permission from Wolters Kluwer Health (Chen J, Peters AM,
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K,
Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK,
Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-actin Leads to NFkappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth Muscle
Cells and Aortic Enlargement Circ Res 2017). See reference (11)

2.14 Statistical analysis
All data are expressed as mean ± standard deviation. Multiple groups were analyzed
assuming unpaired, non-parametric analysis (Kruskal-Wallis). Differences between specific

32

groups were analyzed assuming unpaired, non-parametric analyses (Mann-Whitney U). All
groups included 4 or more male mice depending on the study. I was limited by survival
rates in some of the long term treated Acta2-/- mice although, the analysis consists of 5 or
more animals for most of the studies. Statistical analysis and graphs were all produced with
GraphPad Prism 6 (Version 6.03) or with Microsoft Excel. Differences were considered
significant when p<0.05. However p values approaching the 0.05 limit may be reported if I
felt that it was due to that experiment being underpowered. The Bonferroni correction was
not performed. When shown in the figures, a * indicates p≤0.05, ** indicates p≤0.01, ***
indicates p≤0.001, and **** indicates p≤0.0001.

33

Chapter 3 –The Acta2-/- mouse model of thoracic aortic disease: source of increased AngII
signaling and pharmacologic manipulation of AngII signaling
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3.1 Introduction
As mentioned earlier, in patients with thoracic aortic aneurysm or dissection
(TAAD), it has been shown that up to 20% of them have a genetic predisposition for the
disease (33, 34). Although many of those patients have syndromic features such as Marfan
syndrome, the majority do not have features of a syndrome. These patients show no
specific distinguishable features to identify them to be at risk for thoracic aortic disease
other than a family history of the disease. In these cases, ACTA2 is the most frequently
mutated gene, accounting for 12-20% of the familial mutations making it a specific clinical
concern. ACTA2 encodes the SMC-specific isoform of α-actin (SM α-actin), which makes up
to 40% of SMC cellular protein. SMCs major function is contracting in response to stimuli,
such as cyclic strain or neurostimulation. This cyclic contraction is mediated by sliding thin
filaments composed of α-actin filaments over the thick filaments, composed of SMCspecific β-myosin heavy chain and other proteins. ACTA2 variants causing thoracic aortic
disease are missense mutations inherited in an autosomal dominant pattern, which have
been shown in vitro to cause a dominant negative effect on SMC α-actin filament formation
(5, 41). It is notable that ACTA2 is a highly conserved and invariable gene with essentially
no variation in the general population. Missense variants throughout the protein have
been identified and strong associations exist between specific genotypes and phenotypes
(5). Recurrent mutations disrupting specific amino acids, such p.R179, p.R258, and p.R149,
have sufficient clinical data to identify distinctive clinical phenotypes associated with each
variant and allow for personalized management of the vascular disease associated with
these variants (70-73).
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To model vascular disease in patients with ACTA2 mutations, we used a mouse
model with knock out of SMC α-actin, Acta2-/- mice. Prior studies had shown that Acta2-/mice have normal vascular development, but the mice are hypotensive and aortic
segments contract less with agonist stimulation (67). Work in our lab initially focused on
characterizing the SMC phenotype and determined that Acta2-/- SMCs were hyperplastic
due to activation of cellular pathways, involving FAK, platelet-derived growth factor
signaling, and reactive oxygen species (ROS) (9).
In the studies described below, we sought to characterize aortic pathology in
Acta2-/- mice and determine whether treatment with modulators of the angiotensin system
could alter the pathology. I show that Acta2-/- mice have aortic enlargement, but this
enlargement does not progress to dissection. Furthermore, the aortic enlargement is
attenuated by losartan treatment but exacerbated by captopril treatment. These results
once again emphasize the complex role of angiotensin signaling in aortic disease. Through
my investigations of the cellular mechanisms of aneurysm formation, we identified that
increased NF-κB signaling is responsible for increased expression of Agtr1. The
overexpression of Agtr1 leads to increased sensitivity of the aortic SMCs to endogenous
AngII levels and drives enlargement of the aorta. My results show a completely novel
mechanism by which angiotensin signaling can be increased in cells without an increase in
local or systemic levels of AngII.
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3.2 Results
3.2.1 Acta2-/- mice and losartan treatment over time
There was no difference in the size of the aortic root or the ascending aorta
between Acta2-/- and WT mice at 4 weeks of age (Figure 3.1 A). By 6 months of age, a
significant increase in the size of the aortic root in Acta2-/- mice was evident when
compared to WT mice, and the aortic diameter continued to increase at 7 months of age
(Figure 3.1 B). Interestingly, we observed these changes despite the fact that the Acta2-/mice were significantly hypotensive compared to the WT mice (11). Importantly, there was
no significant difference in mouse survival between the mutant and WT mice (Figure 3.1 C).
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Figure 3.1 – A) At four months of age there was no significant difference between the size
of the ascending aorta and the aortic root between the WT and Acta2-/- mice. B) Over time
the aortic root became significantly larger in the Acta2-/- by 20 weeks of age. C) There was
no difference significant in survival between these mice and their WT littermates. D & E)
Ascending aorta and the aortic root measurements at seven months of age in the Acta2-/with and without treated with losartan. Losartan was able to attenuate the growth of the
aortic root. Note that the ascending aorta is not significantly enlarged in the Acta2-/- mice.
Modified and reprinted with permission from Circulation Research (Chen J, Peters AM,
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu
MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM.
Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased Sensitivity to
Angiontensin II in Smooth Muscle Cells and Aortic Enlargement. Circ Res 2017). See
reference (11)
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I also observed an increase in the number of elastin lamellae in the Acta2-/postnatal aortas when compared to WT aortas (p<0.05, Figure 3.2 A, B). Elastic lamellae
are laid down during development (7, 74), and the increased layers in the aorta can be
observed in the histologic sections at every time point regardless of the treatments or
procedures the mice went through postnatally. A similar phenotype is seen in mice
deficient in elastin, Eln-/- mice (10). At 4 weeks of age Acta2-/- aortas also have an increase
in the density of cells staining positive for a calponin, a SMC marker (Figure 3.3 A, C).
However, the cell density normalizes to the same density as WT by 8 weeks of age, and the
density remains the same as WT at all other time points assessed (Figure 3.2). This data
suggests that the cellular proliferation phenotype and pathways that were previously
identified in Acta2-/- SMCs do alter the development of aortic disease in this mouse. The
pathophysiologic changes seen between the observed groups were consistent with what
we had previously observed in this model. In early studies, we found that there was a
significant increase in the medial area of the Acta2-/- mice while there was no significant
difference in medial cell density at older age. This would possibly indicate some form of
cellular hypertrophy (Figure 3.5). However, the significant difference in medial cell density
at a younger mouse age without increase in medial area may indicate that the cellular
hyperplasia already exist after development.
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Figure 3.2 – A) Aortic medial area increases significantly over time in the Acta2-/- mice
compared to WT mice. B) Medial cell density was significantly higher in Acta2-/- mice
compared to WT shortly after birth, however, the cell density between the mutant and WT
were similar by 3 weeks of age. Modified and reprinted with permission from Circulation
Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S,
Gong L, Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC,
Prakash SK, Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-actin Leads to NFkappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth Muscle Cells and
Aortic Enlargement, Circ Res 2017). See reference (11)
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Figure 3.3 – Histologic analysis of the ascending aortas in mice at four weeks of age. A,B)
Representative H&E, Movat, and calponin stains of the WT and Acta2-/- mice. (A) Show the
increase in elastic lamellae and cells staining positive for calponin (quantified in B).
Modified and reprinted with permission from Circulation Research (Chen J, Peters AM,
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu
MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM.
Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased Sensitivity to
Angiontensin II in Smooth Muscle Cells and Aortic Enlargement, 2017) (11).

Given that losartan blocked aortic enlargement in other mouse models of thoracic
aortic disease (61, 63), we assessed whether losartan treatment could rescue the aortic
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dilation and pathology in Acta2-/- mice. The mice were treated with losartan starting at 4
weeks of age, and treatment continued for six months. The growth of the aortic root was
attenuated with losartan treatment in the Acta2-/- mice compared to WT mice, indicating
that losartan can partially prevent the age-dependent aortic growth (Fig 3.1-D,E). Acta2-/aortas have minimal medial degeneration and the only significant change in aortic
pathology in the mutant aortas compared with WT aortas was an increase in proteoglycan
deposition in the medial layer, and this deposition was prevented by losartan. There were
no significant differences in elastin breaks between Acta2-/- and WT mice. However,
collagen deposition in the adventitial layer was borderline increased (p=0.07) and
attenuated by losartan (p=0.08) (Figure 3.4).
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Figure 3.4 – A) The H&E, Movat, and Sirius Red stains of the WT, Acta2-/-, and Acta2-/losartan treated mice. The Movat stain colors indicate elastin (black), proteoglycans (blue),
and the cells which stained (red). B) Analysis showed that there was a significant increase
in the amount of proteoglycan in the wall of the Acta2-/- mice while there was significantly
less with losartan treatment. C & D) showed that there is no difference in elastin breaks
between the groups. It appears that adventitial collagen is increased, but our study is
underpowered. Modified and reprinted with permission from Circulation Research (Chen J,
Peters AM, Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K,
Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS,
Milewicz DM. Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased
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Sensitivity to Angiontensin II in Smooth Muscle Cells and Aortic Enlargement, Circ Res
2017). See reference (11) .

3.2.2 Long term captopril treatment incapable of reversing pathological changes
associated with Acta2-/- mouse model
Losartan was able to attenuate aortic enlargement in the Acta2-/- mice. We
therefore we wanted to further define the role of the angiotensin system in aneurysm
formation and explore whether other therapeutic targets within this system might be
effective. ACE inhibitors (ACEi) are upstream in the AngII signaling pathway of AngII
receptor blockers, like losartan (Figure 1.5), we tested the use of an ACEi, captopril, in
blocking aortic enlargement in the Acta2-/- mice. Habashi et al. found that they were able
to inhibit aneurysm formation and the angiotensin pathway (65). This captured our interest
given the clinical use of ACEi’s despite the fact that others noted that ACEi (enalapril) were
not as effective in treating aortic aneurysm in Fbn1C1039G/+ (48). ACE inhibitors have been
studied extensively in other tissues (75, 76). For this study, male Acta2-/- mice were treated
for 10 months with captopril, with treatment beginning at 1 month of age. By 11 months of
age, there was no difference in the aortic diameters between the Acta2-/- mice and WT
mice. Surprisingly, there was a significant increase in both the ascending aorta and aortic
root diameter in the Acta2-/- mice treated with captopril compared to WT and untreated
Acta2-/- littermates (Figure 3.4 A & B). Because larger mice tend to have larger aortas, we
also analyzed the data normalizing the aortic size to the weight for all mice. There was no
significant difference in the weight of WT and Acta2-/- mice, but treatment with captopril
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significantly decreased their weight (Figure 3.4 C). As a result, when we normalized to
weight, the difference between the ascending aorta and aortic root size between the mice
becomes more significant even in the ascending aorta (Figure 3.4 D & E).

Figure 3.5 – A, B) Ascending aortic (A) and aortic root (B) measurements at 11 months of
age and 10 months of treatment show that captopril treatment exacerbates the phenotype
of Acta2-/- mice. C) Acta2-/- mice treated with captopril weigh significantly less than wildtype. D, E) Normalizing to weight increases the significant differences between the groups.
* indicates p≤0.05 and ** indicates p≤0.01 in the analysis. (Andrew M. Peters, Zhen Zhou,
Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang,
Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz
Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77).
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Despite exacerbating the dilation of the aorta, captopril treatment did reverse some
of the pathologic changes associated with Acta2-/- aortas. Specifically, the increased medial
and adventitial areas were decreased with captopril treatment. These results suggest that
the thickening of the adventitia and the media is actually protective. Captopril treatment
had no effect on proteoglycan deposition but did increase elastin content in the aortic wall.
The cellular hypertrophy that causes the medial thickening over time does not happen in
the captopril treated aortas, so while elastin content remains constant, the amount of cells
in the wall is lower in the captopril treated mice (Figure 3.6).
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Figure 3.6 – A) H&E and Movat stains of the WT, Acta2-/-, and Acta2-/- mice treated with
captopril. B & C) Analysis indicates that the Acta2-/-mice have a significant increase in the
medial area and the adventitial area. These increases are not seen in the Acta2-/-captopril
treated mice. D) There was a significant increase in the amount of elastin in the medial wall
of the captopril treated mice compared to both the WT and untreated Acta2-/-mice.
(Andrew M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing
Kuang, Shanzhi Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna
M. Milewicz Pharmacologic Manipulation of the Angiotensin System Affects Aortic
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Remodeling and Aneurysm Development: Cautions for Clinical Practice, Submitted 2017)
See reference (77).

“To investigate the increased signaling through the Agtr1a in
Acta2−/− mice, SMCs were explanted from the ascending aorta. Our
previous studies determined that Acta2−/− SMCs have increased
levels of cellular ROS and ERK1/2 signaling (9). To determine
whether Acta2−/− SMCs are more responsive to exogenous AngII,
we assessed pRelA levels. Surprisingly, Acta2−/− SMCs show
activated pRelA in the absence of AngII, whereas WT SMCs do not
(Figure 3.7 A), and this increased pRelA signaling correlates with
increased Il6 expression in the Acta2−/− SMCs [data not shown].
Furthermore, the Acta2−/− SMCs showed increased sensitivity to
AngII and prolonged signaling. In the Acta2−/− SMCs, pRelA levels
increase at 10 nmol/L AngII, whereas pRelA levels do not increase
in WT SMCs until a 100-fold higher dose of AngII is used
(1000nmol/L; Figure 3.7 A; [data not shown]). The Acta2−/− SMCs
are also more sensitive than WT SMCs to exogeneous AngII based
on intracellular Ca2+ assays (Figure 3.7 B). The Acta2−/− SMCs
show earlier and more prolonged increases in pRelA levels than
WT SMCs when exposed to 1 μmol/L AngII [data not shown].
Similar to the Acta2−/− aortas, expression of Agtr1a is increased >8fold in the Acta2−/− SMCs (Figure 3.7 D). For all cellular studies,
Agtr1b expression followed the same pattern as Agtr1a but is ≈10fold lower (data not shown).

We sought to determine the signaling pathway responsible
for increased Agtr1a expression and AngII sensitivity in the Acta2−/−
SMCs. Inhibition of the Agtr1a using losartan effectively blocks the
increase of pRelA in response to exogenous AngII but does not
decrease the basal level of pRelA in Acta2−/− SMCs; Il6 expression
with these treatments correlates with pRelA levels[data not shown].
AngII-induced NF-κB activation in SMCs is mediated by
RhoA/ROCK phosphorylation of Ser536 of RelA (78). Therefore,
Acta2−/− SMCs were exposed to Clostridium botulinum exoenzyme
C3 exotoxin to block Rho activation, which blocks AngII-inducible
pRelA as expected, but does not decrease baseline activation of
RelA in the Acta2−/− SMCs [data not shown]. ROS is a known
activator of NF-κB signaling, and we previously found increased
cellular ROS levels in the Acta2−/− SMCs (9).
Blocking cellular ROS using [N-acetylcysteine (NAC)]
decreases the baseline pRelA levels in the Acta2−/− SMCs and
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reduces the sensitivity of these cells to exogenous AngII (Figure
3.7 C; [data not shown]). NAC treatment also decreases the
expression of Agtr1a, Il6, and Mmp2 in the mutant SMCs to levels
similar to WT SMCs (Figure 3.7 D). Finally, pre-treatment of cells
with NAC abolishes the increase in intracellular calcium in response
to exogenous AngII in both WT and Acta2−/− SMCs (Figure 3.7 E).
To confirm that NF-κB signaling is responsible for the
hypersensitivity of the Acta2−/− SMCs, these cells were treated with
an NF-κB inhibitor anatabine, which partially blocked
phosphorylation of RelA (Figure 3.8 A) and also reduced
expression of Il6, Agtr1a, and Mmp2 to levels similar to WT cells
(Figure 3.8 B). Helenalin, an inhibitor of NF-κB DNA binding
activity, which does not affect RelA phosphorylation, also
significantly blocks expression of Il6, Agtr1a, and Mmp2 [data not
shown)] (79, 80). In addition, pre-treatment of cells with either
anatabine or helenalin abolishes the increase in intracellular
calcium in response to exogenous AngII in both WT and Acta2−/−
SMCs (Figure 3.8 C).
To identify the source of increased ROS, the expressions of
the nicotinamide adenine dinucleotide phosphate (NADPH)
oxidases were assessed, and expressions of Nox4 and p22phox,
along with a known activator of Nox4, Poldip2, are all significantly
increased in the Acta2−/− SMCs (Figure 3.8 D) (81, 82). There is no
significant change in expression of Nox1 or Nox2 [data not shown].
Furthermore, a specific inhibitor of Nox4, VCC588646, reduces
ROS levels in Acta2−/− SMCs and also significantly decreases
expression of Il6, Mmp2, and Agtr1a (Figure 3.8 E & F) (83). NF-κ
B has been previously shown to directly induce Nox4
expression,(84) and treatment with helenalin significantly reduces
expression of Nox4, Poldip2, and p22phox in Acta2−/− SMCs. Taken
together, our data suggest a feedback loop in which increased ROS
levels drive NF-κB signaling that increases Nox4, p22phox, and
Poldip2 expression and ROS accumulation. This feedback loop
increases expression of Agtr1a leading to increased AngII
sensitivity in the aortic SMCs.”
Quoted text reprinted with minimal modification with permission
from Wolters Kluwer Health (Chen J, Peters AM, Papke CL, Villamizar
C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J,
Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK,
Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-actin Leads to
NF-kappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth
Muscle Cells and Aortic Enlargement. 2017) (11)
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Figure 3.7 – Increased sensitivity to angiotensin II (AngII) in Acta2−/−
smooth muscle cells (SMCs) is driven by reactive oxygen species (ROS). A)
Dose–response curve after 20 min of AngII treatment shows that Acta2−/−
SMCs have increased baseline phosphorylate RelA (pRelA) that increases
with exposure to AngII concentrations as low as 10 nmol/L, compared
with 1000 nmol/L in wild-type (WT) SMCs. B) Immediately after
stimulation with various doses of AngII, Acta2−/− SMCs have increased
intracellular Ca2+ levels when compared with WT cells. At least 30 cells
were measured for each group. C) Treatment with N-acetyl cysteine
(NAC) reduces baseline pRelA in Acta2−/− SMCs and reduces AngII-induced
phosphorylation of RelA in both genotypes. D) Acta2−/− SMCs, like the
aortic tissue, have increased expression of Il6, Agtr1a, and Mmp2. NAC
treatment significantly reduces expression of all 3 genes but not to WT
levels. E) Pre-treatment with NAC for 12 h abolishes the increase in
intracellular Ca2+ levels after stimulation with 0.5 μmol/L AngII in both
WT and Acta2−/− SMCs. Modified and printed with permission from
Circulation Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette
LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu MX, Madonna
R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz
DM. Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent
Increased Sensitivity to Angiontensin II in Smooth Muscle Cells and Aortic
Enlargement. Circ Res 2017). See reference (11) ”
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Figure 3.8 – Inhibition of either nuclear factor (NF)-κB signaling or Nox4
reduces Agtr1a expression and decreases sensitivity to angiotensin II
(AngII) in Acta2−/− smooth muscle cells SMCs. A) Helenalin, an inhibitor of
NF-κB signaling, reduces expression of Il6, Mmp2, and Agtr1a after 6 h of
treatment. B) Twelve- hour pre-treatment with helenalin or a second NF51

κB inhibitor anatabine abolishes the increase in intracellular Ca2+ with 0.5
μmol/L AngII stimulation in both wild-type (WT) and Acta2−/− SMCs. C)
Acta2−/− SMCs have increased expression of Nox4, Poldip2, and p22phox
when compared with WT SMCs. D) A specific inhibitor of Nox4,
VCC588646, reduces reactive oxygen species in Acta2−/− SMCs to WT
levels. E) VCC588646 treatment reduces expression of Il6, Mmp2, and
Agtr1a in WT and Acta2−/− SMCs. F) Treatment with the NF-κB inhibitor
helenalin for 6 h reduces expression of Nox4, Poldip2, and p22phox in
Acta2−/− SMCs. Modified and reprinted with permission from Circulation
Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette LJ, Cao JM,
Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu MX, Madonna R, Kee P,
Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. Loss
of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased
Sensitivity to Angiontensin II in Smooth Muscle Cells and Aortic
Enlargement, Circ Res 2017). See reference (11) .

Figure 3.9 – Levels of AngII in Acta2−/− aortas and kidneys are not
significantly different from WT. Measurements were made at 3 mo of age
(n=20 aortas per genotype, 4 kidneys per genotype). Modified and
reprinted with permission from Circulation Research (Chen J, Peters AM,
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L,
Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis
EC, Prakash SK, Kwartler CS, Milewicz DM. Loss of Smooth Muscle alphaactin Leads to NF-kappaB-Dependent Increased Sensitivity to
Angiontensin II in Smooth Muscle Cells and Aortic Enlargement. Circ Res
2017.) See reference (11)
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3.2.3 L-NAME and NAC in Acta2-/- mice
Many of the studies in our lab have focused on the role of blood pressure in aortic
disease. We and others have done numerous studies on mechanical stress and blood
pressure in mouse models. I specifically discuss how we investigate this model in a hyper
acute setting in Chapter 4 (52). Others have also shown that mechanically stressing the
vessels can influence the angiotensin system through a β-arrestin and G-protein mediated
pathway (85).
Given these ideas, we decided to significantly increase the biomechanical stress on
the ascending aorta in the Acta2-/- mice by utilizing a nitric oxide synthase inhibitor, L-NGnitroarginine methyl ester (L-NAME), coupled with a high salt diet (8% NaCl in chow,
Harlan). The regimen made the hypotensive Acta2-/- mice normotensive (Figure 3.10 A)
(11). With the increase in blood pressure, the studies showed that the increase in
biomechanical stress in these mice could lead to a significant increase in aortic root size by
just three months of age compared to the untreated WT and Acta2-/- mice. The ascending
aorta was also significantly enlarged in the normotensive Acta2-/- mice by 3 months of age
(Figure 3.10 B & C). These data show that the forces associated with increased blood
pressure increase the growth rate of the ascending aorta and aortic root in the Acta2-/mice.
We initiated a treatment trial with N-acetyl cysteine (NAC), a broad spectrum
antioxidant, to determine whether reducing ROS could prevent aortic dilation. To better
observe any decrease in phenotype, we chose to use the Acta2-/- mice treated with L53

NAME and high salt diet as these mice have accelerated aortic enlargement. Co-treatment
with L-NAME, high salt diet, and NAC in Acta2-/- mice attenuated the enlargement of the
ascending aorta when compared with WT aortas, but the aortic root still significantly
enlarged (Figure 3.10 B & C). These results suggest that ROS plays a greater role in the
development of ascending aortic enlargement than aortic root enlargement.

Figure 3.10 – A) All tail cuff blood pressure measurements taken in WT mice, Acta2-/- mice
and Acta2-/- treated over the course of the study. Acta2-/- had significantly lower blood
pressure than WT mice. L-NAME and a high salt diet were able to increase the blood
pressure in Acta-/- back to normal. B & C) Treatment with L-NAME and high-salt diet
significantly increases aortic root dilation at 3 months of age. Treatment with L-NAME,
NAC, and high salt diet reduces ascending aortic enlargement. Modified and reprinted with
permission from Circulation Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette
LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ,
Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. Loss of Smooth Muscle alphaactin Leads to NF-kappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth
Muscle Cells and Aortic Enlargement. Circ Res 2017). See reference (11) .

3.2.4 Agtra1-/- and Acta2-/- cross
Since AngII signaling increases superoxide production by activating NADPH oxidases
in SMCs (86), we crossed the Acta2-/- mice and the Agtr1a-/- mice to determine if ROS are
increased in the Acta2-/- aortas without AngII signaling from the Agtr1a receptor. Agtr1a-/54

mice are hypotensive and have thinner aortic walls than WT, but do not develop
aneurysms. The aortic tissue is more friable and falls apart easily on dissection, making it
difficult to work with these mice. I was unable to determine whether aortic dilation was
decreased or pathologic endpoints were altered in the Acta2-/- Agtr1a-/- double mutant
mice because the significant hypotension complicated interpretation of the data. Instead,
we hypothesized that we would not block the increased ROS signaling in the aorta if the
Agtr1a receptor was not present, i.e., ROS would still be increased due to the loss of SM αactin. Acta2-/- Agtr1a-/- double mutant mice were born in the expected Mendelian ratio,
despite having lower blood pressures than the Acta2-/- mice (Figure 3.11 C). Both DHE
staining and lucigenin assays indicate decreased ROS in Acta2-/- Agtr1a-/- mice compare to
the Acta2-/- mice, suggesting that Agtr1a activity is partially, but not completely,
responsible for the increased ROS. Importantly, the Acta2-/- Agtr1a-/- aortas still have
significantly higher ROS levels than WT. Furthermore, the expression of Il6 and Mmp2
remains higher in the Acta2-/- Agtr1a-/- double mutant aortas than WT aortas, suggesting
that pathways other than Agtr1a contribute to the activation of these genes. Expression of
other renin-angiotensin system components was not significantly different in Acta2-/Agtr1a-/- mice compared with the single mutants (Figure 3.11).
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Figure 3.11 – Addition of the Agtr1a-/- allele into Acta2-/- mice does not completely prevent
increased ROS A) frozen DHE staining of aortic sections indicate that ROS levels in the
aortas of Acta2-/- Agtr1a-/- mice are higher than in WT mice, but lower than in Acta2-/- mice.
B) NADPH oxidase activity in the Acta2-/- Agtr1a-/- is not different compared to Acta2-/- and
WT mice. C) Acta2-/- Agtr1a-/- mice have significantly lower systolic blood pressure than
Acta2-/- mice. D) Expression of Mmp2 is elevated in the Acta2-/- Agtr1a-/- mice compared to
WT. E) Components of the RAS system appear to not be affected by the loss of Agtr1a.
Modified and reprinted with permission from Circulation Research (Chen J, Peters AM,
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu
MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM.
Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased Sensitivity to
Angiontensin II in Smooth Muscle Cells and Aortic Enlargement, Circ Res 2017). See
reference (11) .
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3.3 Discussion
I found that NF-κB signaling driven by increased cellular ROS leads to an
increase in expression of the Agtr1a. The increased expression of Agtr1a in aortic
SMCs then leads to activation of AngII-dependent signaling at AngII levels that were
100 fold lower than that required in WT SMCs in vitro, as assessed by phosphorylation
of RelA and increased intracellular Ca2+. Acta2-/- aortas have increased levels of ROS
and phosphorylated RelA. Increased expression of Agtr1a is also observed. When the
Agtr1a receptor is deleted in the Acta2-/- mice, ROS levels remain elevated. This result
indicates that increases in ROS and downstream molecular changes do not
completely depend on exogenous AngII signaling through Agtr1a in the Acta2-/- aortic
SMCs. Exogenous AngII further augments both ROS and NF-κB signaling in the mutant
cells. In turn, this drives a feedback loop resulting in further increases in ROS and NFκB signaling (Figure 3.12). Others groups have shown that when ROS is increased in
SMCs by overexpression of p22phox, an important subunit for all NADPH oxidases, SMC
hypertrophy driven by AngII is potentiated, making ROS a potential therapeutic target
(87). My results indicate that increased cellular ROS in the p22phox-overexpressing
SMCs could activate NF-κB signaling, increasing the expression of Agtr1a. This ends
up potentiating AngII signaling in aortic SMCs.
The Acta2-/- mice develop dilation of the aortic root by 6 months of age. This is
similar to the aortic root enlargement observed in patients with ACTA2 mutations (70), and
aortic root dilation is attenuated with losartan, an Agtr1a and Agtr1b blocking agent (ARB).
However, aortic growth is not completely reversed. Losartan treatment attenuates pRelA
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signaling but not through ERK1/2 signaling, suggesting that ERK1/2 activation is driven by
other pathways. Knocking out Agtr1a in Acta2-/- mice does not decrease ROS levels to
those of WT. This suggests that increased ROS and downstream molecular changes are not
dependent on exogenous AngII signaling through the Agtr1a in the Acta2-/- aortic SMCs in
vivo. The baseline increase in ROS and/or the pathways driving ERK1/2 signaling may be
responsible for losartan not completely reversing aortic enlargement. We note that
significant hypotension in Acta2-/- mice limits forces on the ascending aorta thereby
attenuating aortic enlargement in this mouse model. L-NAME and a high salt diet
increased the blood pressure to levels similar to the WT mice and also significantly
increased the aorta growth rate. This is consistent with current data that suggests blocking
nitric oxide (NO) signaling protects the aorta from enlargement in mouse models of
aneurysms (88), and excessive signaling through a target downstream of NO signaling, type
I cGMP-dependent protein kinase, can drive thoracic aortic disease (89). Therefore, the
significantly increased growth rate of the aorta in the Acta2-/- mice after L-NAME treatment
is due to increased biomechanical stress on the aorta not inhibition of NO-synthase.
There was a significant increase in elastic lamellae in our mice in addition to an
increase in SMCs, similar to what is reported with the Eln-/- mice (10). I note that patients
with ELN hemizygosity show a similar phenotype with supravalvular aortic stenosis and an
increase in elastic lamellae (90, 91). As stated previously, the number of lamellar units is
based biomechanical properties (6), and Eln+/- mice are hypertensive. The increased
lamellae in these mice are likely due to the increased blood pressure and increased
biomechanical stress in the wall (92) . The same cannot be said in the hypotensive Acta2-/58

mice, but in culture Acta2-/- SMCs are stiffer than WT SMCs (11), so cellular stiffness, rather
than global wall, stress could be responsible for the increase in lamellar units in the Acta2-/aortas. Alternatively, the increased elastin lamellae laid down during development could
be due to increased proliferation of the mutant SMCs. It is known that Acta2-/- SMCs
proliferate more rapidly the WT SMCs in vivo and in vitro (9). Eln+/- SMCs also proliferate
more rapidly than WT cells (13). Therefore, it is possible that the increased elastin lamellae
laid down in both mouse models may be a result of the increased proliferative capacity of
these mutant cells.

Figure 3.12 - Model of dysregulated signaling in Acta2-/- SMCs showing the feedback loop
linking reactive oxygen species with angiotensin signaling in Acta2-/- SMCs. Reprinted with
permission from Circulation Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette
LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ,
Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. Loss of Smooth Muscle alphaactin Leads to NF-kappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth
Muscle Cells and Aortic Enlargement, Circ Res 2017) See reference (11) .
59

The use of an ACEi, captopril, did not inhibit aneurysm formation in these mice.
Instead it exacerbated the phenotype. My results differ from studies using other mouse
models of thoracic aortic disease. Long-term treatment with captopril reversed aortic
pathology, aortic growth, and aortic rupture in the Fbln4-/- mouse (65). Additionally, aortic
disease in the Fbn1C1039G/+ mouse was attenuated by treatment with another ACEi,
enalapril. My cellular studies suggest that AngII signaling in SMCs could be increased
without increased exogenous AngII, which may partially explain the failure of captopril
treatment to attenuate growth. However, the exacerbation of the aortic enlargement in
the Acta2-/- mice when these mice were treated with captopril has thus far not been
explained. The next chapter (pg. 55) will further explore pharmaceutical manipulation of
the AngII signaling pathway in another model of thoracic aortic disease.
We also tested whether the MMP inhibitor, doxycycline, could alter aortic
pathology in Acta2-/- mice (data not shown). In the hypomorphic Marfan mouse model,
Fbn1mgR/mgR mice, doxycycline was able to increase their lifespan by about 53 days with
decreased elastin breaks and levels of Mmp2 and Mmp9 expression (68). Another group
showed that combining losartan and doxycycline could synergistically prevent thoracic
aortic aneurysms in Fbn1C1039G/+ mice by down regulating Mmp2 and Mmp9 and restoring
the structural integrity of the wall (63). However, my results were inconclusive as to
whether doxycycline decreased aortic enlargement in the Acta2-/- mice. These studies
were complicated by the fact that sugar water was used to dissolve the bitter tasting
doxycycline, and this increased the weight of the treated mice and the size of their aortas.
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We failed to control for the increased weight by giving the control mice sugar water.
Furthermore, the study was most likely underpowered to determine differences between
the groups.
Next, I hypothesized that development of aortic disease in Acta2-/- mice was
hindered by hypotension. I showed that making them normotensive with a combination of
L-NAME and high salt diet drastically accelerated and exacerbated the phenotype over
time. To further assess the role of biomechanical forces in driving the disease, we
attempted to use constriction of the thoracic aorta to increase biomechanical forces on the
ascending aorta (see methods for details) on the Acta2-/- mice (unpublished data).
However, we were unable to get results from this study because the majority of the Acta2/-

mice died when they were anesthetized for surgery, including in sham operated mice.

The high death rate is most likely due to the hypotension in the Acta2-/- mice. We also had
increased peri-operative mortality with the TAC procedure in Agtr1a-/- mice, which are also
hypotensive. I conclude that hypotensive mouse models are unable to survive the stress
associated with anesthesia and surgery.
In the end, I was able to show that disrupting SM α-actin sensitizes the aortic SMC
to exogenous AngII by increasing ROS and NFκB signaling, leading to an increase in the
expression of Agtr1a. I confirmed this pathway is also activated using pharmacologic
disruption of SM α-actin filaments in vitro (data not shown) (11). Blocking both ROS
production with NAC and the AT1R with losartan attenuated aortic growth in the Acta2-/mice. Based on the signaling pathways identified in these studies, blocking NF-κB signaling
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should also block aortic growth, and these pathways may also be effective therapeutic
targets in other patients with disruption in SM α-actin filament formation.
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Chapter 4 – Pharmacological manipulation of AngII signaling in the TAC mouse model of
thoracic aortic aneurysm formation
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4.1 Introduction
As mentioned earlier, the major risk for thoracic aortic aneurysms and dissections is
hypertension. In fact, any condition that increases biomechanical forces on the ascending
aorta increases the risk for thoracic aortic disease. Uncontrolled essential hypertension is
the most concerning risk factor, but other conditions that increase blood pressure also
predispose to aortic disease such as cocaine or stimulant use, weight lifting, the Valsalva
maneuver, and congenital defects that constrict the aorta like aortic coarctation (32).
While Chapter 3 has addressed altered genes that predispose to the disease, hypertension
can lead to earlier onset thoracic aortic disease in individuals with and without a genetic
predisposition.
I have adopted a mouse model of an acute increase in biomechanical forces to
assess how increased biomechanical stress leads to aortic enlargement. A transverse aortic
constriction (TAC) is created by constricting the aorta between the first two major vessels
branching off the aorta, the innominate and left common carotid (Section 2.3) (52). The
model has been used extensively to study pressure-induced cardiac hypertrophy due to
hypertension or aortic stenosis. With the acute constriction of the transverse aorta, the
blood pressure increases proximally on the heart, ascending aorta, and right carotid artery.
The increased pressures lead to hypertrophy of the left ventricle within two weeks after
placement of the constriction (93). Subsequently, the left ventricle dilates, and congestive
heart failure ensues (66, 94). TAC results may vary due to different surgeons, anesthesia
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and surgical techniques, and various other factors such as suture migration (94-96). Hence,
the precise phenotype present in each of these models is open to interpretation.
Before mice develop heart failure after TAC, increased left ventricular pressure and
hypertrophy of the heart produces significant increase in biomechanical forces on the
ascending aortic wall proximal to the site of constriction. Therefore, I used this model to
study aortic remodeling due to increased biomechanical forces on the ascending aorta and
limited all analyses to two weeks after constriction so that forces continuously increased
on the aorta and our results were not complicated by heart failure. After two weeks, the
ascending aorta dilates and there is thickening of the medial and adventitial layers in the
aortic wall. The medial layer thickens due to widening between the elastin layers without
evidence of hyperplasia, suggesting SMC hypertrophy. The adventitial layer increases in
area and cell density due to accumulation of collagen, myofibroblasts, and macrophages.
Inflammatory markers are increased, including interlukin-6 (IL6) and monocyte
chemoattractant protein 1 (MCP-1), and remodeling factors like matrix metalloproteinase 2
(MMP2) and matrix metalloproteinase 9 (MMP9) also increase in expression (52).
The pathologic changes associated with aortic remodeling with TAC are similar to
the pathologic changes in the aorta associated with AngII infusion (28, 30, 57). This
suggests that AngII signaling may drive the hypertension-associated remodeling. We
hypothesized that utilizing an ARB, losartan, would alter the response and prevent the
observed pathologic changes and aortic enlargement. The administration of losartan 3 days
prior to TAC and for two weeks post operatively eliminated the vascular inflammatory
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response, including the macrophage accumulation. Losartan partially rescues the TACinduced adventitial hyperplasia, collagen accumulation, and ascending aortic dilatation.
Therefore, I concluded that signaling through the AT1R was completely responsible for the
vascular inflammation and partially responsible for the TAC-induced aortic remodeling.
At the outset of these studies, the signaling downstream of AT1R was the interest.
It is well established that there are different intracellular pathways associated with the
AT1R, only some of which are ligand-dependent (97). I was specifically interested in the
ligand independent pathways that had been investigated in the heart. Known to play a part
in load induced hypertrophy, it was shown in vivo and in vitro that stimulation of the AT1R
independently of AngII leads to translocation of G-proteins into the cytosol via Janus kinase
2. This activation was inhibited by another ARB, candesartan (64). Later, it was shown ex
vivo that mechanical stretch mediates a confirmation change in β-arrestin, driving signaling
consistent with ligand mediated AT1R signaling. Hearts from mice lacking β-arrestin or the
AT1R did not respond to the mechanical stress (85). The ligand-independent activation of
AT1R in vascular SMCs has also been investigated. Mechanical signaling of the Agtr1a to
activate SMC’s in mesenteric and renal arteries did not rely on ion channels TRPC6 or
KCNQ3, 4, or 5 for SMC (98). However, in FbnC1039G/+ mice, studies suggested that β-arrestin
contributed to thoracic aortic aneurysm formation in Marfan syndrome (99). Hence, we
wanted to investigate the ligand independent activation of the AT1R in our TAC model.
At the initiation of these studies, we sought to confirm whether the remodeling is
due to an increase in circulating AngII levels or if ligand-independent signaling is a more
important driver of disease. To test this hypothesis, we administrated an ACE inhibitor to
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block conversion of angiotensin I to angiotensin II to see if it prevented hyper-acute aortic
remodeling in our TAC model.

4.2 Results
4.2.1 Treatment with captopril fails to rescue remodeling associated with TAC
Wildtype C57BL6/J male mice (12 weeks of age) underwent TAC or sham surgeries
with or without treatment with either losartan or captopril to determine if captopril could
prevent pathologic remodeling as effectively as losartan. All treatments were started ~72
hours prior to surgery with losartan and captopril given via drinking water at 600 mg/L or
75 mg/L, respectively. Initial experiments showed a significant decrease in survival with
captopril treatment (Figure 4.1 A) despite the fact that the losartan mice were significantly
more constricted than the captopril treated group (Figure 4.1 B). Necropsy results from our
preliminary study showed multiple deaths due to aortic rupture or dissection in the
ascending aorta. I first noted that only mice treated with captopril were acutely dying
post-operatively for no apparent reason. Prior TAC studies performed by this surgeon did
not result in similar deaths, so I began to investigate whether and how captopril might be
causing death. I performed surgery on a second group of mice and monitored survival rates
closely, with necropsy performed on any non-surviving mice. Closer examination indicated
that only mice treated with captopril were acutely dying outside of what we considered the
perioperative window. Therefore, I began to monitor the mice more closely in the second
preliminary group and the monitored survival rates after post-op day five were consistent
67

with our first group and necropsies were routinely performed. Two mice treated with
captopril following TAC specifically stood out. Prior to echocardiography on day 14, one
mouse exhibited behaviors consistent with significant discomfort and pain. Necropsy
revealed an intramural hematoma in this mouse (Figure 4.1 C). Another visibly healthy
mouse acutely died after post-op day five, and gross examination of the ascending aorta
indicated a dissection that started in the ascending aorta. Histologic examination of the
same mouse indicated that blood was present in the vessel wall near the pulmonary artery
(Figure 4.1 D & E).
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Figure 4.1 – A) The survival curve after TAC and treatment with either losartan or captopril.
Only mice treated with captopril died after TAC. B) The increased deaths of the mice
treatment with captopril were not due to increased constriction as measured by
RCCA/LCCA ratio. C) Prior to echocardiography on day 14, this mouse exhibited behaviors
consistent with significant discomfort. After necropsy, thorough cleaning of the aorta
revealed and intramural hematoma (red arrow). D) Gross examination of the ascending
aorta of another mouse who on necropsy who died acutely indicated a dissection that
started in the ascending aorta (red arrow). Histologic examination of the same mouse, (F)
indicated that blood was present in the vessel wall (red arrow) near the pulmonary artery.
* indicates p≤0.05.

These initial experiments were repeated by a different surgeon performing the TAC.
There was a significant increase in the ascending aorta and aortic root diameter between
the WT sham controls and WT TAC mice (Figure 4.2 A, B, & C). As in my previous study,
aortic growth was attenuated by losartan treatment compared to untreated TAC mice in
the ascending aorta and aortic root. Captopril treatment, on the other hand, was unable to
attenuate the increase in size of the ascending aorta or aortic root in these mice to the
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same extent as the losartan treatment. In contrast to the previous studies, none of the
captopril treated mice died after the five day peri-operative period.
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Figure 4.2 – A) In our third set of studies, echoes from the four different groups were
obtained in our WT sham, TAC, TAC+captopril, and TAC+losartan treated groups. The
approximate locations of the measurements are indicated in the sham image. B & C) The
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increase in the ascending aorta and in the aortic root size was significant in the untreated
TAC mouse compared to sham. Losartan was able to attenuate the increase in size as
previously observed. However, TAC mice treated with captopril was not attenuated. D) As
previously, the level of constriction was verified via Doppler flow studies indicating
successful constriction in all TAC mice. E) Successful constriction in TAC mice were also
verified by measuring blood flow across the constriction in the transverse aorta. * indicates
p≤0.05, ** indicates p≤0.01, *** indicates p≤0.001, and **** indicates p≤0.0001. (Andrew
M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang,
Shanzhi Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M.
Milewicz Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling
and Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference
(77).

The level of constriction was accessed by comparing the ratio of Doppler velocities
between the right common carotid artery (RCCA) and the left common carotid artery
(LCCA) (RCCA/LCCA). In my original studies, a successful constriction was considered a ratio
between 5-10 which was also consistent with what was seen in literature and our
preliminary studies (52, 66). It is important to note that the ratios in the constricted groups
were consistently above 10 without a decrease in survival rates (Figure 4.2 D), which was
higher than the ratio in our previous studies (Figure 4.1 B). We also assessed blood flow
across the aortic constriction in these mice as this has been reported to be another method
to assess the level of constriction (100). It was significantly elevated in all the TAC groups
compared to the sham, and there was no significant difference between the TAC groups
(Figure 4.2 E).
Histologic analysis of the TAC mice showed that the increase in vascular and
adventitial area was similar between the losartan and captopril treated groups (Figure 4.3
A, B, & C). These results reflected the observations in my first study, but my earlier
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histopathologic measurements were too underpowered to indicate a significant different
between the medial area in these groups (data not shown). The adventitial cell density
decreased significantly in the captopril treated group compared to the non-treated TAC
group and sham control (Figure 4.3 D), and the medial cell density significantly decreased
in both TAC and TAC + Captopril groups compared to the sham controls (Figure 4.3 E).
Additionally, inflammatory markers including IL6, MCP-1, MMP2, and MMP9 remained
elevated under captopril treatment compared to WT sham (data not shown), but this was
difficult to assess given these markers were nearly undetectable in my WT sham cohort.
The changes in the structure of the aortic wall were consistent with our previous TAC
studies with an increased distance between the elastic lamellae increased number of Mac2 positive cells in untreated and captopril treated TAC mice (Figure 4.4 A). The increase in
distance between the lamellae coupled with the significant decrease in medial cell density
could indicate that there is significant SMC hypertrophy. The expansion of the adventitia
also appeared to consist largely of proteoglycans along with inflammatory cells. In the
media, we verified that there was a significant increase in elastin breaks in the mice
undergoing TAC that was not attenuated with captopril treatment (Figure 4.4 B). We also
observed a significant increase in the proteoglycans in the medial layer in addition to what
we observed in the adventitia (Figure 4.4 C). Cell counting confirmed that there was a
significant increase in inflammatory cells that was not reversed with captopril treatment
(Figure 4.4 D).
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Figure 4.3 – A, B, & C) H&E stains showing that captopril did not alter the increase in
vascular or adventitial area. D) Treatment with captopril in TAC mice increased adventitial
cell density compare to both the sham and TAC controls. E) Medial cell density was also
significantly decreased in the TAC and TAC + captopril mice compared to sham controls. *
indicates p≤0.05, ** indicates p≤0.01, *** indicates p≤0.001, and **** indicates p≤0.0001.
(Andrew M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing
Kuang, Shanzhi Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna
M. Milewicz Pharmacologic Manipulation of the Angiotensin System Affects Aortic
Remodeling and Aneurysm Development: Cautions for Clinical Practice, Submitted 2017)
See reference (77).
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Figure 4.4 – A) Movat stains (top) show the changes in the structure of the aortic wall were
consistent with my previous TAC studies showing an increased distance between the elastic
lamellae increased number of Mac-2 positive staining cells in untreated and treated TAC
mice. B) There was significant increase in elastin breaks in the mice undergoing TAC, and C)
increase in the proteoglycan in the medial layer. D) Cell counting confirmed that there was
a significant increase in inflammatory cells that was not reversed with captopril treatment.
* indicates p≤0.05, ** indicates p≤0.01, and *** indicates p≤0.001. (Andrew M. Peters,
Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi
Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz
Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77).
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4.2.2 C21 is beneficial in biomechanical stress model
There are additional receptors involved in that angiotensin system other than the
ligand dependent or independent signaling of the AT1R (See section 1.3, pg. 10). Therefore,
I sought to characterize the role of the AT2R and Mas receptor in the captopril treated TAC
mice by treating with agonists for these receptors: compound 21 (C21) is an agonist for the
AT2R while AVE0991 is an agonist for the Mas receptor. I focused on the physiologic
changes associated with treatment. Ultrasound examination of the ascending aorta and the
aortic root again showed a significant increase in aortic size in the ascending aorta, which
was not attenuated with captopril. Co-treatment with C21 was able to eliminate the
increase in the ascending aortic diameter, but it only attenuated the increase in size in the
aortic root. Meanwhile co-treatment with AVE0991 with captopril had no effect on the
ascending aorta or aortic root compared to untreated or captopril treated mice and
remained significantly elevated compared to mice treated with both captopril and C21
(Figure 4.5 A & B). As with previous studies, I verified the level of constriction using the
ratio between the left and right carotid (RCCA/LCCA) and flow across the constriction site
(Figure 4.6 C & D).
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Figure 4.5 – A & B) Echoes of the ascending aorta and the aortic root again showed a
significant increase in the ascending aorta size which was not attenuated with captopril.
Co-treatment with C21 was able to eliminate the change in the ascending aorta and
attenuate it in the root. Meanwhile co-treatment with AVE0991 and captopril had no effect
compared to untreated mice. C & D) We verified that the constriction in the untreated and
treated mice were similar between groups using two methods. * indicates p≤0.05, **
indicates p≤0.01, *** indicates p≤0.001, and **** indicates p≤0.0001. (Andrew M. Peters,
Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi
Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz
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Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77).

In our original publication on aortic remodeling with TAC, we did not assess blood
pressure (52). For the studies reported here, I assessed blood pressure and pulse pressure
in the ascending aorta by inserting a catheter into the right carotid artery and advancing it
to the ascending aorta. There was a significant increase in systolic blood pressure in the
TAC mice, and systolic blood pressure was significantly decreased in both treatment
groups. In contrast, the diastolic blood pressure was not different between the TAC and
sham group. However, the losartan and captopril treated mice both had significantly lower
diastolic blood pressure (DBP) compared to sham and TAC controls in the ascending aorta
(Figures 4.6 A & B). There was no difference in pulse pressure between any of the treated
or untreated in mice that underwent TAC (Figure 4.6 C), which was interesting since cyclic
strain has been directly correlated with vascular disease in the carotid arteries (101).
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Figure 4.6 – With an intraluminal catheter, we directly measured the A) systolic and B)
diastolic blood pressure in the groups. C) Pulse pressure was then calculated. All TAC mice
had significantly increased systolic blood pressure, but the blood pressure in mice treated
with losartan and captopril were significantly lower. The losartan and captopril treated
mice also had significantly decreased diastolic blood pressure compared to both sham and
untreated TAC mice, but the pulse pressure was consistent in all mice treated with TAC. *
indicates p≤0.05 and ** indicates p≤0.01. (Andrew M. Peters, Zhen Zhou, Jiyuan Chen,
Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, Siddharth Prakash,
GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz Pharmacologic Manipulation of
the Angiotensin System Affects Aortic Remodeling and Aneurysm Development: Cautions
for Clinical Practice, Submitted 2017) See reference (77).

Lastly, mice undergoing TAC were treated with C21 alone, which was able to
decrease the ascending aorta similar to the captopril and C21 treated mice but not the
aortic root when compared to the untreated TAC mice (Figure 4.7). As expected, direct
measurement of the systolic blood pressure (SBP) in the ascending aorta and aortic root
was significantly increased in all mice that underwent TAC. Any combination of the
pharmaceutical agents was capable of decreasing the SBP however, all remained elevated
compared to WT sham mice. While diastolic blood pressure (DBP) remained normal in the
untreated TAC mice, all treated TAC mice had a significant decrease in DBP compared to
sham and control mice (Figure 4.8). These results are consistent with our earlier study,
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which indicated TAC mice had increased pulse pressure with or without any
pharmaceutical manipulation.

Figure 4.7 – Ultrasound assesments of the aortic root and ascending aortic diameters in WT
sham, TAC, TAC + losartan, TAC + captopril, TAC + captopril + AVE0991, TAC + captopril+
C21, and TAC + C21. The number of observations for each group is listed at the bottom of
each graph, and significant p values are listed above. As expected TAC mice had an increase
in the size of the aortic root and ascending aorta compared to sham mice, and losartan was
able to attenuate these changes. Captopril alone was not able to attenuate the increase,
and the combination with AVE0991 did not show any significant changes compared to the
untreated mice. Captopril in combination with C21 was able to significantly decrease the
increase in aortic size. Alone, C21 was only able to decrease the ascending aorta when
compared to the untreated TAC mice. (Andrew M. Peters, Zhen Zhou, Jiyuan Chen,
Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, Siddharth Prakash,
GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz Pharmacologic Manipulation of
the Angiotensin System Affects Aortic Remodeling and Aneurysm Development: Cautions
for Clinical Practice, Submitted 2017) See reference (77).
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Figure 4.8 – As expected, direct measurement of the systolic blood pressure (SBP) in the
ascending aorta and aortic root was significantly increased in all mice that underwent TAC.
Any combination of the pharmaceutical agents was capable of decreasing the SBP, but they
all remained elevated compared to WT sham mice. While diastolic blood pressure (DBP)
remained normal in the untreated TAC mice, all treated TAC mice had a significant
decrease in DBP compared to sham and control mice. (Andrew M. Peters, Zhen Zhou,
Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang,
Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz
Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77).

The aortic pathology was also assessed in these aortas from animals treated with
losartan, captopril, and captopril plus the agonists. The pathologic changes in the
adventitia in the losartan and captopril treatment were consistent with what was
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previously shown (Figure 4.3). Interestingly, there appeared to be little change in the
adventitia with co-treatment of captopril and C21 or C21 alone. However, treatment with
captopril and AVE0991 decreased both the medial and adventitial area with an increase in
adventitial cell density and decrease in medial cell density (Figure 4.9). There was
significant proteoglycan deposition in the adventitia in all groups.
Next, vascular inflammation was assessed by Mac-2 staining for macrophages in the
adventitia. TAC causes significant increases macrophage positive cells in the adventitia, and
losartan completely blocks the accumulation of Mac-2 positive cells in the adventitia.
However, captopril and co-treatment with C21 or C21 alone do not appear to decrease this
accumulation of Mac-2 cells in the adventitia. In contrast, co-treatment of captopril and
AVE0991 completely eliminate Mac-2 positive cells the inflammatory response in the
adventitia (Figure 4.11). Sirius red staining for collagen deposition indicated a significant
increase in the adventitial fibrotic response with TAC. This response was attenuated with
losartan but remained elevated with captopril treatment and C21 with and without
captopril. Interestingly, AVE0991 treatment with captopril significantly decreases the
amount of collagen in the adventitia (Figure 4.12).
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Figure 4.9 – Preliminary H&E stains (n=2) confirming what was previously observed in all of
our earlier published and unpublished studies. TAC increased medial and adventitial
thickening, and losartan treatment was able to attenuate it. Losartan was able to attenuate
the changes. While captopril attenuated the changes in the medial layer, it appeared to not
do so in the adventitial layer, and the pathologic changes in the adventitia observed in
these mice were consistent with what was previously shown. There appeared to be little
change with co-treatment of captopril and C21 or C21 alone, but treatment with captopril
and AVE0991 appeared to significantly both medial and adventitial area. There also
appeared to be an increase in adventitial cell density. Note that p values not calculated.
(Andrew M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing
Kuang, Shanzhi Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna
M. Milewicz Pharmacologic Manipulation of the Angiotensin System Affects Aortic
Remodeling and Aneurysm Development: Cautions for Clinical Practice, Submitted 2017)
See reference (77).
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Figure 4.10 – Movat staining (n=2) shows increased proteoglycan deposition in the
adventitial layer. There was an increase in the distance between the elastic lamellae in TAC
mice, and significant proteoglycan deposition in the adventitia. These observations
appeared slightly attenuated in the losartan treated mice, but was absent in the captopril
and AVE0991 treated mice. While the adventitia appears larger compared to the WT sham
controls, there appears to be less proteoglycan deposition and more cells in the wall. Note
that p values not calculated. (Andrew M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda,
Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, Siddharth Prakash, GenTAC
Consortium, Callie S. Kwartler, Dianna M. Milewicz Pharmacologic Manipulation of the
Angiotensin System Affects Aortic Remodeling and Aneurysm Development: Cautions for
Clinical Practice, Submitted 2017) See reference (77).
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Figure 4.11 – Mac-2 staining of the aortas (n=2). TAC significant increases macrophage
positive cells in the adventitia, and losartan attenuates it. Captopril and co-treatment with
C21 or C21 alone do not appear to decrease this inflammatory response. Co-treatment of
captopril and AVE0991 appeared to completely eliminate the inflammatory response in the
adventitia. Note that p values not calculated. (Andrew M. Peters, Zhen Zhou, Jiyuan Chen,
Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, Siddharth Prakash,
GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz Pharmacologic Manipulation of
the Angiotensin System Affects Aortic Remodeling and Aneurysm Development: Cautions
for Clinical Practice, Submitted 2017) See reference (77).
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Figure 4.12 – Sirius red staining (n=2) in the cells indicated a significant increase in the
adventitial fibrotic response, and it was attenuated with losartan but remained elevated
with captopril treatment. It appears to be slight decreased with C21 with and without
captopril. AVE0991 treatment with captopril and TAC significantly decrease the amount of
collagen in the adventitia. Note the absence of p values. (Andrew M. Peters, Zhen Zhou,
Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang,
Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz
Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77).

4.2.3 Knock out of Agtr1a fails to alter vascular inflammation
Given the effectiveness of losartan in previous studies (61, 65), I set out early to try
to perform TAC in Agtr1a-/- mice. We expected results similar to those observed in
pharmaceutically treated mice in Agtr1a-/- mice. The Agtr1a-/- mice are hypotensive
compared to WT controls (Figure 4.13). My early results indicated a significantly decreased
peri-operative survival rate making my study difficult. Because of my concerns regarding
possible flaws in my original study, this was repeated with two different surgeons. After
the peri-operative period, surviving Agtr1a-/- mice were not significantly different than the
WT untreated TAC mice. Vascular and adventitial area remained elevated in WT and
Agtr1a-/- untreated mice. Investigation of inflammatory markers such as Mac-2 indicated
that inflammation was attenuated in Agtr1a-/- TAC mice (Figure 4.14). Therefore, we
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investigated the difference between the WT and Agtr1a-/- mice. Agtr1a-/- mice have
decreased medial area compared to WT mice, but the medial area is significantly increased
compared to Agtra1-/- mice after TAC. Vascular and adventitial expansion are still present in
Agtr1a-/- TAC mice compared with both WT and Agtr1a-/- sham controls (Figure 4.15). TAC
Agtr1a-/- mice show increased distance between the elastic lamellae, but Agtr1a-/- mice
appear to have more elastic lamellae, and early results in other studies have indicated that
they are less developed.

Figure 4.13 – SBP and DBP measurement taking in WT and Agtra1-/- mice to verify their
decreased blood pressure. All measurements taken by tail cuff following the protocol
previously mentioned (Section 2.5). ** indicates p≤0.01.
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Figure 4.14 – My preliminary studies in mice deficient in Agtr1a did not have the same
effect as while type mice treated with losartan. A, B, & C) Vascular and adventitial area
remain elevated in WT and Agtr1a-/- treated mice. D) While inflammation appeared to be
attenuated in these mice, the number of Mac-2 positive cells was only attenuated in
Agtr1a-/- mice.
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Figure 4.15 – A, B, & C) Agtr1a-/- mice have decreased medial area compared to WT mice,
but the medial area is significantly increased compared to Agtra1-/- mice after TAC. C & D)
Significant vascular and adventitial expansion is still present in Agtr1a-/- mice compare to
both sham controls. E) There is a significant increase in SMCs in the media under control
conditions. F & G) When analyzed by weight, the ascending aorta is significantly lower in
the sham mice compared to WT sham, but there is no difference between the two in the
aortic root.
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Figure 4.16 – Significant adventitial expansion remains in the TAC Agtr1a-/- compared to
WT and Agtr1a-/- mice who underwent sham surgery. TAC Agtr1a-/- mice show increased
distance between the elastic lamellae, but Agtr1a-/- mice appear to have more elastic
lamellae and early results appear less developed.

4.3 Discussion
We have previously shown that signaling through the AT1R is responsible for a
significant portion of the aortic remodeling that occurs with TAC. A prominent component
of TAC-induced aortic remodeling is vascular inflammation characterized by increased Il6
and Mcp1 expression and recruitment of macrophages to the adventitia, and these
changes are completely blocked when signaling through the AT1R is prevented by
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treatment with losartan. Other changes are only partially blocked, including ascending
aortic dilatation, adventitial cellular hyperplasia and collagen accumulation. I initially
hypothesized that the AT1R activation was not due to increased AngII in aortic tissue, but
rather mechanical stretch activation of the AT1R, which has been described in
cardiomyocytes and SMCs (64, 85, 98, 99). Furthermore, it has been shown that inverse
agonists of the AT1R can block this activation of the AT1R (102). Although losartan is not
an AT1R inverse agonist, EXP3174, an active metabolite of losartan, can act as an inverse
agonist in the inositol phosphate (IP) production assay based on studies involving a
constitutively active AT1-N111G mutant (103). To begin to investigate whether AT1R
activation with TAC-induced aortic remodeling was ligand independent, I blocked the
production of AngII using captopril. Indeed, captopril did not block the aortic dilatation and
vascular remodeling associated with TAC, supporting the conclusion that the AT1R
activation in SMC with TAC is ligand independent. At the same time, the initial experiments
suggested that captopril had a negative effect on aortic remodeling, leading to increased
deaths due to aortic rupture.
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Figure 4.17 – Working model indicating my points of interest in the angiotensin system.
The questions remaining are the influence of the AT2R and Mas receptor in our hyperacute model specifically in the ascending aorta and how they could modulate the ligand
independent signaling.

I sought to determine the role of signaling through other receptors in the
angiotensin system with TAC when all AngII signaling is blocked and aortic remodeling is
dependent on mechanical stimulation. AT2R receptors are present in vascular SMCs, and
have been reported to comprise approximately 30% of the AngII receptors in the rat aorta
(104). It is feasible that AT1R activation proceeds unchecked when all the receptors are
blocked but selective activation of AT2R could block aortic enlargement to the same extent
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as losartan treatment alone. As stated above (Section 1.3), the AT2R has been known to
counter the effects of the AT1R downstream in multiple systems. In the vascular SMCs, the
AT1R increases proliferation, fibrosis, MMP2, and MMP9 expression (52), while the AT2R
decreases proliferation, fibrosis, and MMP9 and MMP2 expression (48, 105). However, in
some models the AT2R has been thought to affect smooth muscle cell apoptosis (53, 54)
Another ACEi, enalapril, was used to reinforce the importance of the AT2 receptor.
A cross between the FblnC1039G/+ with mice deficient in AT2R, Agtr2-/y (106), actually
increased aneurysm formation and made losartan less effective (48). Their results indicated
the AT2R decreases pERK signaling, cell proliferation, fibrosis, and MMP9 signaling. Their
results were reinforced by other labs, which showed that antagonists of the AT2R are
detrimental in abdominal aortic models. In ApoE-/- mice infused with AngII, the antagonist
of the AT2R, PD123319, leads to an increase in atherosclerosis and AngII induced vascular
pathology (107). However, they later showed PD123319 could work by an AT2R
independent mechanism, which complicates interpretation of their results (108). Still, the
independent beneficial effects of the AT2R could possibly explain why captopril was not
just ineffective but detrimental.
Ang1-7 is a peptide mainly generated from AngII by angiotensin converting enzyme
2 (ACE2), but which can also be made from AngI via neutral endopeptidase activity. Ang1-7
binds to the G protein-coupled receptor Mas. In SMCs, Mas receptor signaling is considered
an antagonist of AngII signaling. Mas receptor signaling is vasodilatory and blocks
hypertrophy and migration of SMCs. Importantly, Ang1-7 blocks the pro-inflammatory
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response triggered by AngII in primary human SMCs in culture by blocking NF-κB signaling
and inducible nitric oxide synthase induction. With exposure to AngII, SMCs activate NF-κB
signaling, and Ang1-7 markedly inhibits this activation and the associated inflammatory
changes (109). Specifically, Ang1-7 suppresses superoxide anion levels and NADPH oxidase
activity that occurs in SMCs with exposure to AngII (110), but does not have these effects
on SMCs in the absence of AngII exposure. In our studies of TAC-induced aortic remodeling
and blocking angiotensin signaling through the major receptors, selective activation of the
Mas receptor agonist completely blocked vascular inflammation based on decreased Il6
and Mcp1 expression and lack of macrophage accumulation in the adventitia. At the same
time, aortic enlargement was not rescued and the aortic pathology was adversely affected.
The Mas agonist prevented SMC hypertrophy and instead caused SMC loss in the aortic
media and decreased fibrosis in the adventitial layer. The loss of SMCs is in contrast to a
protective role of the Mas receptor in other cells types.
Ang1-7 has been studied extensively in multiple systems. In the kidney, its
activation has been associated with decreased matrix protein production and improved
renal function and its inhibition associated with increased collagen deposition, TGF-β,
Smad2/3, ERK1/2, and NFKβ (55). In rat models, Ang 1-7 was shown to improve heart
function by reducing cardiomyocyte hypertrophy, fibrosis and inflammatory cell infiltration
with short term administration. In the cerebrovasculature, in a study of intracerebral
hemorrhagic stroke with C57BL/6 mice, it was shown to modulate NF-κB signaling by
decreasing TNF-α, MCP-1, and IL-8 (111). Of interest to me, another group utilized mice
deficient in ACE2, Ace2-/y (112) and the AngII infusion model to study the thoracic aorta.
94

They were able to find ACE2 deficiency worsened the AngII mediated inflammation model
with enhanced AKT phosphorylation, increased ERK1/2, and increased endothelial nitric
oxide synthase. These results could be reversed with an ARB, irbesartan, that prevented
inflammation by suppressing the Akt-ERK-eNOS signaling pathway (113). Therefore, the
loss of SMCs and other adverse pathologic changes with TAC when the Mas receptor is
activated suggests that ROS generation with TAC plays a protective role in aortic SMCs.
While our focus is on the angiotensin system, we must remember the kinin system
also influences the vascular disease. Kininogen is metabolized by kallikrein into bradykinin.
Bradykinin, a fundamental part of the kinin system, has been a well-established vasodilator
helping to control blood pressure. It has also been associated with increased vasodilation,
vascular permeability, inflammation, and pain. ACE is one of the major vasopeptidases
regulating bradykinin signaling as it metabolizes bradykinin into its inactive forms.
Subsequently, ACEi use has been shown to increase nitric oxide and vasorelaxation (114).
Hence, the kinin system may play a role in the results I observed with captopril. While
inhibiting both AT1R and AT2R, we may have left bradykinin uninhibited resulting in our
increased inflammation observed with captopril treated mice compared to losartan treated
mice.
Finally, I sought to determine how TAC-induced aortic remodeling would occur with
loss of the AT1R. These studies were complicated by the fact that the Agtr1a-/- mice are
significantly hypotensive and appear underdeveloped ascending aortas. Interestingly
deletion of Agtr1a-/- in mice has been associated with a variety of factors including
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increased life expectancy (115, 116), but diminished growth, vascular thickening, and
atrophy of the inner renal medulla (117). Despite these issues with the aorta, it was still
surprising that TAC induced medial wall thickening, adventitial thickening, and vascular
inflammation were present in the Agtr1a-/- mice. We expected our results to be similar to
the mice treated with losartan. Based on the pharmacologic manipulation of aortic
remodeling with TAC, these changes are proposed to be in part due to ligand independent
activation of AT1R. Despite this conclusion, it is clear that mechanical forces are still able
to cause remodeling in the absence of the Agtr1a. It is notable that not all TAC-induced
remodeling is blocked by losartan (52), but the influence of deleting a gene in a highly
variable system is difficult to predict. In such a dynamic system, there is no guarantee that
another signaling pathway does not become more dominant or compensates for the loss of
the Agtr1a receptor. Humans only have one isoform of the AT1R, but mice have two, and in
the kidney the absence of once can be compensated by the other isoform (117). In this
model, Agtr1b is still present, and it is yet unknown how it might affect the cell types in the
ascending aorta and whether it can compensate for the loss of Agtr1a. Others have found
Agtr1b to be more mechanosensitive in vascular SMC myogenic vasoconstriction (118). This
model would need to be studied more extensively to verify the role of Agtr1b in TACinduced remodeling of Agtr1a-/- mice.
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Chapter 5 – Discussion and Conclusions
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5.1 Introduction
I hypothesized that angiotensin II signaling through the AT1R contributes to thoracic
aortic aneurysm formation in multiple model systems of disease, but that blocking related
receptors in addition to the AT1R, such as the AT2R and Mas receptor, may have negative
consequences. In the Acta2-/- mouse model, I found an increased sensitivity of cells to AT1R
signaling without exogenous AngII was due to increased ROS and NF-ΚB signaling. Acta2-/mice develop dilated aortas over time, and the dilation is partially blocked with an ARB,
losartan, but blocking the formation of the ligand with an ACEi, captopril, was insufficient
to attenuate disease. In TAC, I again found that ARB treatment attenuated the physiologic
and pathophysiologic changes I observed, but captopril did not. The combination of
captopril and C21 had the same physiologic affect as an ARB. However, the results did not
coincide with the pathophysiologic changes.
Angiotensin signaling was initially identified as a system to manage the blood
pressure in response to different environmental stimuli. As described in Chapter 1,
angiotensinogen is converted to angiotensin I by renin which is then converted to the
ligand AngII by ACE (24). Investigations into AngII signaling were at first primarily focused
on the renal response to manage blood pressure, but over time research has been
expanded to identify a role for angiotensin signaling in other systems, such as the heart
and aorta (50, 51).
In addition to its function in regulating blood pressure, the renin angiotensin system
is also known to be involved in triggering inflammation and fibrosis during remodeling of
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multiple organ systems including the kidneys and the heart. In the kidneys, the reninangiotensin-aldosterone-system plays a role in both hypertensive and end-stage kidney
disease (119). The invasion of fibroblasts and the fibrotic response eventually lead to the
destruction of nephrons and the interstitium of the kidney, resulting in kidney failure (120).
In patients, the administration of ARBs has been shown to improve proteinuria, indicating
improved kidney function and reinforcing the beneficial aspects of ARBs and their
relationship to fibrosis (121). In the heart, a similar fibrotic response has been observed. It
has been well established that angiotensin signaling and downstream aldosterone signaling
have been associated with increased collagen synthesis and deposition (122). They have
also been associated with degenerative remodeling of the heart, restricted blood flow, and
heart failure (103). In investigations of these models, data has consistently shown that
these changes involved TGF-β signaling in the fibrotic response (75).
5.2 Role of angiotensin signaling in TAAD
The work presented in this dissertation furthers understanding of the role of
angiotensin signaling in thoracic aortic remodeling and disease. First, we addressed the role
of blocking all angiotensin receptors using an ACE inhibitor, captopril. Previous studies had
shown another ACE inhibitor, enalapril, was not as effective as losartan in preventing aortic
growth in the Marfan mouse model (48). Interestingly, in the Fbln4-/- mouse model,
captopril was as effective as losartan in preventing many of pathologic changes associated
with the disease such as an increase in vascular area (65). I found that captopril actually
increased aortic growth in both the aortic root and ascending aorta of the Acta2-/- mouse
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model and worsened elastin breaks compared with no treatment. In our TAC model of
acute hypertension, treatment with captopril did not prevent aortic enlargement and
vascular inflammation, whereas treatment with losartan did. These results provide
additional data to support that ACE inhibitors are not equivalent to ARBs in terms of
treating thoracic aortic disease.
In the Acta2-/- mouse model, we identified that the source of increased AngII
signaling in the aorta was not an increase in ligand. Rather, there was a significantly
increased sensitivity of the AT1R to endogenous levels of AngII due to ROS increasing NF-κB
signaling, which drives increased expression of AT1R (11). It is important to note that the
Fbn1-/- mice may also have increased AT1R expression since these mice also show
increased ROS in SMCs and aortic tissues.
We intended to use the data from the TAC captopril trial to show that TAC-induced
AT1R signaling in the ascending aorta and aortic root was not dependent on the ligand,
AngII. Surprisingly, our original captopril trials gave an overwhelmingly poor outcome with
50% of the mice dying. Replication of the study by a different surgeon did not demonstrate
the increased death rates. However, captopril did not rescue the aortic remodeling induced
by TAC. Markers of vascular inflammation remained elevated in the captopril treated TAC
mice, and the aortic root and ascending aorta enlarged despite decreased systolic
pressures in the ascending aorta. These results support our hypothesis that ligandindependent AT1R signaling is important in driving aortic disease but also raised the
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question of whether other components of the angiotensin system may play a role in the
remodeling.
5.3 Angiotensin signaling through AT1R
In the past 10 years, angiotensin signaling through AT1R has emerged as a potential
therapeutic target to prevent thoracic aortic disease. Initially, losartan was used to block
canonical TGF-β signaling in the Marfan mouse model. Additional studies showed that
losartan could block thoracic aortic disease in multiple mouse models, including our own
studies of aortic enlargement in the Acta2-/- mice (52, 61). Since blocking TGF-β signaling
using losartan was so effective in the Marfan mouse model, the use of an ARB as a receptor
blocker to prevent aortic disease in Marfan patients has been tested in multiple clinical
trials (123). Many of these trials compared ARB treatment to β-adrenergic blocking agents
which are considered the gold standard for treatment of aortic disease under the belief
that it reduces stress on the aorta by reducing left ventricular ejection fraction and heart
rate (123, 124). These studies focused on aortic growth rates but included other endpoints
including aortic surgery and acute aortic dissection.
5.4 Clinical relevance
At least eight randomized clinical trials of losartan in patients with MFS were
initiated worldwide. The first prospective trial completed was the Dutch COMPARE trial,
which assessed 233 MFS patient over the age of 18 years who met diagnostic criteria for
MFS and were assigned to receive losartan or no additional medications beyond “usual
therapy”, which commonly included a β-blocker. After a mean follow up of 3.1 years,
101

losartan significantly reduced the rate of aortic root dilation when compared with “usual
therapy” with the caveat that more patients in the losartan group than in the “usual care”
group took β-blockers (125). Importantly, a sub study analyzed the 117 MFS patients with
characterized FBN1 mutations and determined that only individuals with haploinsufficiency
mutations (n=38, 32.5%), but not individuals with missense mutations (n=79, 67.5%), had a
reduction in the rate of aortic root dilation with losartan treatment (126). Other outcomes
beyond rate of aortic root dilation have not been reported for the COMPARE trial.
The US Pediatric Heart Network Trial was the largest losartan trial (127). It enrolled
608 patients with MFS between the ages of 6 months and 25 years who met Ghent criteria
and had significant aortic root enlargement (defined by a Z score > 3.0). The two arms of
the randomized trial were atenolol (started at 0.5mg/kg/day and increased on the basis of
hemodynamic response to a maximum of 4mg/kg/ day) and losartan (started at 0.4
mg/kg/day and increased on the basis of hemodynamic response to a maximum of 1.4
mg/kg/day). The “mean” dose for young adults was 151 mg atenolol per day and 85 mg of
losartan per day. The main outcome of the trial did not show any significant difference in
the rate of aortic root growth between the groups. Similarly, two other double blind clinical
trials testing losartan against atenolol (128) or against placebo (129) showed no effect of
losartan in limiting aortic dilatation. In contrast, a small open label pilot study in 28 patients
with MFS found reduced rate of aortic dilation with losartan added on to β-blockade
therapy (130). Other clinical studies are still ongoing and results have not been published.
Although the US Pediatric Heart Network trial was designed to examine rate of
aortic root growth as the primary outcome and there was no difference between groups, a
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combined secondary endpoint (death, dissection, aortic root surgery) was reached over the
3 years clinical trial period in 10 of 268 atenolol-treated patients and in 19 of 267 Losartantreated patients. This event rate was almost 2-fold higher in the losartan treated patients,
but did not reach statistical significance (p value = 0.07). The study was not sufficiently
powered to examine clinical endpoints of dissection, death, and aortic root surgery, in part
due to the fact that these events are fortunately very rare in a young cohort like the
Pediatric Heart Network study. Assuming a similar cohort of MFS patient and the same
statistical parameters as used for the US Pediatric Heart Network study with an 85% power
to detect a difference at the level of significance of 0.05, a sample size of 760 patients may
have reached a statistically significant increase for combined secondary endpoints of
dissection, aortic surgery, or death in the losartan-treated group. However, this is
speculative, and extrapolation of the observed event rate in the US Pediatric Heart
Network trial is uncertain since it occurred exceedingly rarely. But the results from this trial
raise the important point that future clinical studies cannot focus on aortic dilatation alone,
and must include clinically important outcomes such as dissection and need for aortic
surgery. The p-value of 0.07 indicates that there is a 93% chance that the increased
combined frequency of dissection, death, and aortic root surgery in the losartan-treated
MFS patients in the US Pediatric Heart Network trial did not occur randomly. Importantly,
other smaller clinical trials comparing β-blockade to losartan did not have increased events
in individuals treated with losartan.
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5.5 The fibrotic response
These results bring up an interesting question: is it possible that the fibrotic
response seen in many of the models may not be detrimental but beneficial? Angiotensin II
blockade with enalapril was recently reported to reduce the progression of cardiac fibrosis
in patients with Duchenne and Becker muscle dystrophy in a small randomized clinical trial
(131, 132). While reduced cardiac or renal fibrosis might improve the functions of these
organs, it could be of disadvantage for the aorta, where tensile strength is required to
withstand the force of pulsatile blood flow. Biomechanical studies show that the wall
increases in thickness to better distribute the hoop stress in response to an increase in
pulse pressure (25). We also know that AngII signaling drives a fibrotic response in the
thoracic aorta stimulating fibroblast and myofibroblast proliferation and recruiting
macrophages and monocytes. Eventually, this leads to adventitial thickening and
deposition of increased extracellular matrix (28, 30). The thickening of the medial and
adventitial layer and increased fibrosis with TAC is a physiologic response to increased wall
stress.
Hence, blocking aortic fibrosis driven by TGF-β or AngII signaling may not be the
correct pharmacological target to block aneurysm growth. This view is supported by
multiple observations. First, mutations in genes encoding proteins in the TGF-β canonical
signaling pathway lead to decreased TGF-β signaling in smooth muscle cells but actually
cause heritable thoracic aortic disease (8). It is counter-intuitive to further block TGF-β
signaling in these individuals to prevent aortic disease. Second, blocking TGF-β signaling in
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the MFS mouse model through knockout of the TGF-β type II receptor or knockdown of
TGF-β2 increases aneurysm formation (133, 134). Third, blocking TGF-β signaling in
another mouse model for aortic aneurysms, AngII infusion, increases the penetrance and
severity of aneurysms and deaths due to aortic rupture (135). Finally, loss of function
mutation of lysyl oxidase, an enzyme mediating collagen crosslinking and strongly linked to
mechanical stability of extracellular matrix and fibrosis, were recently identified as
causative for familial thoracic aortic aneurysms and dissections (136, 137). Blocking TGF-β
signaling or blocking proper collagen maturation disrupts the integrity of the thoracic
aorta.
AngII signaling also drives fibrosis in the adventitial layer of the thoracic aorta.
AngII stimulates aortic adventitial fibroblasts to recruit monocytes via secretion of MCP-1,
and the recruited monocytes further activate the fibroblasts/myofibroblasts to proliferate
and deposit extracellular matrix, leading to adventitial thickening (28, 105). Although this
process occurs as part of aneurysm formation associated with AngII infusion, the same
vascular inflammation and adventitial fibrosis occurs when the forces are increased on the
aorta by thoracic aortic constriction and this hypertensive remodeling is attenuated by
losartan (52). Therefore, aortic adventitial remodeling driven by signaling through the
AT1R can be physiologic to adapt to increased pressures or pathologic and associated with
aneurysms. The unanswered question is whether blocking this adventitial fibrotic
remodeling through the use of losartan will increase the risk for aortic dissection or
rupture.
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5.6 Angiotensin signaling through AT2R
I asked whether signaling through the AT2R or the Mas receptor might be
important in TAC-induced aortic remodeling. Dramatic differences in terms of aortic
growth and aortic pathology were found when agonists of the AT2R or the Mas receptor
were used with captopril in TAC mice. The AT2R agonist, C21, in combination with captopril
was able to prevent aortic enlargement but not vascular inflammation in this model
system. Almost the exact opposite was found when the Mas receptor agonist was used –
aortic enlargement was not rescued but vascular inflammation and much of the associated
adventitial fibrosis was completely blocked. These results support that additional studies
must now focus on the use of AT2R agonists as potential therapeutics to help prevent
thoracic aortic disease. Although the Mas receptor agonists have shown to be beneficial in
skeletal and heart diseases, the profound aortic pathologic changes, including collapse of
the aortic media with SMC loss, and the continued enlargement of the aorta indicate that
activation of the Mas receptor is not a target for thoracic aortic disease.
5.7 Study limitations
Several limitations of my studies should be kept in mind when considering my
conclusions. First, in many experiments there was insufficient statistical power.
Furthermore, I did not account for the Bonferroni correction in any of my calculations. This
may have altered some of the statistical significance in my results. Second, all of my studies
focused on aneurysm formation but did not effectively investigate the risk for dissections
and how they relate to the angiotensin system in these models. Ideally, a model that more
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consistently causes aortic dissection should be utilized for future studies. While some of my
necropsy studies indicated possible dissections, the frequency of the finding was not
consistent enough to draw conclusions. Our lab is currently attempting to define better
mouse models for aortic dissection. Once those models are established, one of the first
goals should be to assess whether changes in the fibrotic or inflammatory responses
associated with the angiotensin pathway may hinder or exacerbate dissection.
5.8 Future directions
Moving forward, we should pay closer attention to the difference between the
ascending aorta and the aortic root. We know that they are derived from distinct
developmental origins (3), but how does that specifically affect their different responses to
the same stimulus? Recent results have also indicated an inducible nitric oxide synthase
was potential therapeutic target (88), and it would be interesting to determine how the
AT2R or Mas could play a role in this system. Finally, I would also be interested in going
back and to address my original question about which intracellular pathway downstream of
the AT1R is activated in the ascending aorta in response to biomechanical stress.
My goal at the start of this project was to identify pathways that might improve the
treatment of thoracic aortic aneurysms. I believe that the results of my studies contribute,
in a small way, to our understanding of therapeutic strategies targeting the angiotensin
system. While ARBs are considered the therapeutic with the highest potential of all the
pharmaceutical manipulations of the angiotensin system, the angiotensin system is far
more complicated and dynamic than most would have ever anticipated. Much more time
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needs to be invested in our understanding of the angiotensin system in thoracic aortic
disease, and we should not assume that blocking particular receptors or pathways in other
systems, such as the kidneys or heart, will also be beneficial in the thoracic aorta. We must
carefully choose our experimental designs to better investigate disease pathologies and
possible therapeutic strategies.
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